Northeastern Section AUA 6 1ST A N N U A L M E E T I N G Scientific Program Visit us at Facebook.com and search for Northeastern Section Connect with Other Attendees View Scheduled Events Post Discussions NS-AUA 2009 Annual Meeting CONTENTS Welcome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2 Needs Assessment and Learning Objectives . . . . . .4 CME Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5 Meeting-at-a-Glance . . . . . . . . . . . . . . . . . . . . . . . . . .6 Schedule-at-a-Glance . . . . . . . . . . . . . . . . . . . . . . . . .7 Officers and Committees Listing . . . . . . . . . . . . . . . . .10 Research Education Fund/Supporter Recognition . .11 Past Presidents and Meeting Venues . . . . . . . . . . . . .12 George E. Slotkin Lecturers . . . . . . . . . . . . . . . . . . . . .13 Invited Speakers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .14 Scientific Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . .18 Social Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .31 Quick Guide to Montreal . . . . . . . . . . . . . . . . . . . . . . .35 Exhibitor Listing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .37 Exhibitor by Booth Number / Exhibit Floor Plan . . . .41 Disclosure Information . . . . . . . . . . . . . . . . . . . . . . . . .42 CME Credit Form . . . . . . . . . . . . . . . . . . . . . . . . . . . . .43 PROG RAM COM M ITTEE Pierre I. Karakiewicz, Chair Serge Carrier Peter Chan Bruno Laroche Armondo J. Lorenzo Dawn MacLellan Robert K. Nam D. Robert Siemens Martine Jolivet Tremblay Alexandre R. Zlotta ARRANG EM ENTS COM M ITTEE Julie Franc-Guimond, Co-Chair Paul Perrotte, Co-Chair Juan Diego Barrieras Serge Carrier I NVITED S PEAKERS George E. Slotkin Lecture Sir. Philip G. Ransley Gerald B. Brock Martine Jolivet-Tremblay Eric A. Klein John M. Fitzpatrick Edward M. Messing Robert M. Moldwin Francesco Montorsi J. Curtis Nickel Shahrokh F. Shariat 1 NS-AUA 2009 Annual Meeting Dear Colleagues and Friends, It is my honor to invite you to the 61st Annual Meeting of the Northeastern Section of the American Urological Association (NS-AUA). Nearly twenty years ago I attended my first NS-AUA meeting at the encouragement of my mentor, Dr. B.M. Churchill. I believe this sectional meeting is a unique occasion to share Canadian perspectives and experiences with our American colleagues. It gives us a distinct opportunity to discuss controversial issues and novelties with renowned experts in a somewhat “intimate” setting. Coupling a state-of-the-art scientific program with the inimitable backdrop of the beautiful and historic Montréal, this year’s Annual Meeting is sure to be a success. Dr. Pierre Karakiewicz, Program Chair, and his team have organized an exciting educational program including distinguished expert speakers, point-counterpoint debates and clinically relevant plenary sessions to ensure an exceptional educational value of the meeting. Hot topics to be discussed at the plenary sessions include: Erectile Dysfunction after Radical Prostatectomy; Stress Urinary Incontinence and Unstable Bladder; Prostate Cancer and Chemo Prevention; Locally Advanced and Metastatic Kidney Cancer; Kidney Cancer and Androgen Deprivation Therapy; Prostatitis, Benign Prostatic Hyperplasia and Unstable Bladder. Invited speakers include: Sir Philip Ransley, MD, the George F. Slotkin Lecturer; Gerald Brock, MD; Martine Jolivet-Tremblay, MD; Eric A. Klein, MD; John Fitzpatrick, MD; Edward Messing, MD; Robert M. Moldwin, MD; Francesco Montorsi, MD; J. Curtis Nickel, MD and Shahrokh Shariat, MD. We are also very excited to once again feature a one-day Nursing Program on Friday, October 9, 2009. Drs. Paul Perrotte and Julie Franc-Guimond have organized a fun-filled social program highlighting many of Montréal’s unique cultural offerings. Join us for a night at the circus on Friday for the Fun Night event at Cirque Éloize! The renowned Cirque Éloize training center, located in Old Montréal, will be the setting for our cocktail reception and dinner for this incredible night of entertainment. Guests can take advantage of the Botanical Garden, Insectarium and Biodôme tour on Friday as well at the Old Montréal Historical Tour on Saturday. The closing banquet on Saturday night will feature Dr. Richard Béliveau, researcher and author of three books on nutrition and cancer. Dr. Béliveau and the hotel chef have designed an exquisite menu for this event that coincides with Dr. Béliveau’s cancer-fighting research On behalf of the entire organizing committee, I look forward to seeing you in Montréal! Anne-Marie Houle President, Northeastern Section of the AUA 2 Northeastern Section of the AUA — 2009 Annual Meeting Chers(ères) Collègues et Amis(es), C’est avec beaucoup d’enthousiasme que je vous invite chaleureusement à participer au 61ième Congrès Annuel de la section Northeastern de l’Association Américaine d’Urologie (NS-AUA). Il y a déjà 20 ans, à la suggestion de mon mentor le Dr. BM Churchill, j’assistais à mon premier congrès de la section. J’ai alors découvert un forum unique pour partager et discuter des perceptives et expériences canadiennes distinctives avec nos collègues américains. Le congrès offre aussi une occasion peu commune de débattre des sujets les plus chauds et controversés et d’être initié aux plus récents développements en urologie avec un accès privilégié aux experts reconnus dans ces domaines. Avec la vie socio-culturelle trépidante de Montréal en toile de fond et un programme scientifique à la fine pointe, le congrès annuel de 2009 promet d’être un évènement à ne pas manquer. Dr. Pierre Karakiewicz, Directeur Scientifique du Congrès, et son équipe, ont déjà confirmé une brochette de conférenciers exceptionnels et développé un programme éducationnel interactif excitant incluant débats, panels et plénières. La dysfonction érectile post prostatectomie radicale, l’incontinence urinaire et l’hyperactivité vésicale, la chimio prévention du cancer de la prostate, le cancer du rein localement avancé ou métastatique, la prostadynie et le syndrome de douleur pelvienne constituent les sujets chauds qui se partageront la vedette. La liste de nos conférenciers invités est des plus impressionnantes avec Sir Philip Ransley, MD, le conférencier George F. Slotkin; Gerald Brock, MD; Martine Jolivet-Tremblay, MD; Eric A. Klein, MD; John Fitzpatrick, MD; Edward Messing, MD; Robert M. Moldwin, MD; Francesco Montorsi, MD; J. Curtis Nickel, MD and Shahrokh Shariat, MD. Cette année sera aussi marquée par la deuxième édition d’un programme distinct d’une journée spécialement conçu pour les infirmiers et infirmières en urologie du territoire de la section qui se tiendra le 9 octobre 2009. Les Drs. Paul Perrotte and Julie Franc-Guimond ont mis sur pied un programme d’activités sociales mettant en valeur les principaux atouts de Montréal. La soirée de bienvenue au Fairmont Reine Élisabeth soulignera l’engagement de Montréal pour notre sport national, le hockey, avec des activités appropriées et des surprises de taille. Vendredi soir, nous célèbrerons nos artistes de cirque avec le Cirque Éloize qui nous accueillera dans ses installations d’entraînement dans le Vieux Montréal et qui se produira au cours de la soirée. Durant la journée, les accompagnants pourront profiter de visites guidées du Jardin Botanique, de l’Insectarium et du Biodôme vendredi et du Vieux Montréal, samedi. Le banquet de clôture aura lieu dans la salle de bal du Reine Élisabeth et mettra en vedette le Dr. Richard Béliveau, chercheur et auteur réputé dans le domaine de la nutrition et la prévention du cancer. Le chef exécutif du Fairmont et le Dr. Béliveau uniront leurs savoirs et savoir-faire pour nous concocter un menu aussi raffiné et exquis que santé. Au nom de tout le comité organisateur, je vous invite à vous joindre à nous à Montréal du 7 au 11 octobre 2009 pour le Congrès annuel de la NS-AUA. Nous vous attendons en grand nombre. Anne-Marie Houle Président, Northeastern Section of the AUA 3 N EEDS AS S ES S M ENT The field of urology is in constant evolution and established practices need to be periodically updated. This year’s Annual Meeting will provide participating urologists with several such updates. The topics will focus on urologic malignancies (e.g., prostate, bladder and renal cancers), as well as non-malignant pathologies (e.g., benign prostatic hypertrophy, urinary incontinence, prostatitis, overactive bladder and hypogonadism). Urologic malignancies contribute to a significant proportion of urologic referrals. In the past decade the treatment algorithms have changed for patients with renal cancer. Patients with small renal masses may benefit from multiple treatment alternatives, which range from surgery to surveillance. Patients with unresectable or metastatic renal cancer can now benefit from an array of systemic therapies. The urologist needs to play a central role, as cytoreductive nephrectomy and metastasectomy remain key management components for such patients and their timing is crucial. In the field of prostate cancer, several paradigms have changed. For example, controversy exists regarding screening. Novel preventive modalities will soon be introduced. Finally, the long-term risks and benefits of androgen ablation therapy affect the timing, the duration and the patterns of administration of this treatment modality. In bladder cancer several therapeutic alternatives exist for patients with non-muscle invasive high risk disease. These issues will be addressed in the program. Despite the importance of urologic malignancies, the bulk of urologic referrals are for non-malignant pathology. Prostatitis, benign prostatic hypertrophy, overactive bladder, hypogonadism and erectile dysfunction represent some of many common urologic complaints. Despite their apparent simplicity, the investigation and/or management of these conditions may represent a challenge. Moreover, novel pharmacological management options have multiplied for several of these conditions. For example, the number of medical management options for overactive bladder has increased exponentially. Conversely, effective treatment options for patients with prostatitis remain scarce. To address the diagnosis and management of these urologic conditions, the 2009 NS-AUA Annual Meeting will feature a total of 10 presentations that will be complemented by an equal number of expert panels and additional point-counterpoint sessions. Eight poster sessions will cover these areas with expert moderated discussions around the presented topics. Overall, the state-of-the-art lectures, podium and poster sessions presented by many North American and European experts promise to deliver excellent educational value. The meeting will offer up to 18.75 AMA PRA Category 1 Credits™. LEARN I NG OBJ ECTIVES At the conclusion of the 2009 NS-AUA Annual Meeting, participants should be able to: I interpret and evaluate the existing evidence in favor and against prostate cancer screening I critically appraise the data on available chemoprevention therapies for prostate cancer I weigh the pros and cons of early vs. delayed androgen deprivation therapy and critically appraise the value of continuous vs. intermittent therapy I critically appraise the risks and benefits of intravesicle therapy relative to early cystectomy for non-muscle invasive high risk bladder cancer patients I gain a thorough understanding of medical management of overactive bladder I obtain an update of available management options and their efficacy for patients with chronic prostatitis I review the magnitude of urologic risks associated with testosterone supplementation I examine the value of available treatment regimens for erectile dysfunction in the aging male, as well as after urologic surgery I reassess the central role of the urologist in the management of surgically unresectable and metastatic renal cancer, and become familiar with the existing molecules for the management of unresectable and/or metastatic renal cell carcinoma and with the common toxicities 4 Northeastern Section of the AUA — 2009 Annual Meeting C O N T I N U I N G M E D I CA L E D U CAT I O N Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The AUA takes responsibility for the content, quality and scientific integrity of this continuing medical education (CME) activity. Credit Designation: The AUA designates this educa- tional activity for a maximum of 18.75 AMA PRA Category 1 Credits™ . Physicians should only claim credit commensurate with the extent of their participation in the activity. provide members of the audience with information on which they can make their own judgments. Unlabeled or Unapproved Use of Drugs or Devices: It is the policy of the AUA to require the disclosure of all references to unlabeled or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this CME activity may contain reference(s) to unlabeled or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses. Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA. AUA Disclosure Policy: As a provider accredited by the ACCME, the AUA must insure balance, independence, objectivity and scientific rigor in all its activities. All faculty participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the faculty’s relationships may influence the educational content with regard to exposition or conclusion and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent faculty with relevant financial relationships from serving as faculty, but rather to Evidence-Based Content: As a provider of CME accredited by the ACCME, it is the policy of the AUA to review and certify that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous and free of commercial bias. Special Assistance/Dietary Needs: The AUA, an organization accredited for CME, complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, a written request should be submitted at least one month in advance. For additional assistance with your request please call 410-689-4025. 5 Meeting at-a-Glance TH U RS DAY, OCTOB ER 8, 2009 I Plenary/Guest Lectures: ED, Kidney Cancer, Testosterone Supplementation, Prostatitis, BPH and Unstable Bladder I Moderated Poster Session: Prostate Cancer, Basic Research, Robotics, Endoscopy and Laparoscopy, and Bladder Cancer I Sneak Peek Luncheon in Exhibit Hall I Exhibit Hall Grand Opening/Welcome Reception I Networking Reception FRI DAY, OCTOB ER 9, 2009 I 5K Fun Run/Walk Tour of Botanical Gardens, Insectarium & Biodome I Industry-sponsored Breakfast Symposium Sponsored by VIVUS, Inc. I Prize-Winning Essays I Nursing Program I Plenary/Guest Lectures: Prize-Winning Essays, PSA Screening, Prostate Cancer Chemoprevention I AUA Course of Choice I Moderator Poster Sessions: Pediatric Urology, Oncology, General Urology and Kidney Cancer I Exhibit Hall Open I Fun Night at Cirque Éloize I Spouse SATU RDAY, OCTOB ER 10, 2009 I Industry-sponsored Breakfast Symposium Sponsored by Ferring Pharmaceuticals I Residents Program Business Meeting I Plenary/Guest Lectures: Pediatric Urology, Androgen Deprivation Therapy, Stress Urinary Incontinence and Unstable Bladder I George F. Slotkin Lecture I Tennis Tournament I Tour of Old Montréal I President’s Reception & Banquet I Annual EXH I B IT HALL HOU RS Thursday, October 8 Friday, October 9 Noon – 3:30 p.m. 5:30 – 6:30 p.m. 9:30 a.m. – 1:30 p.m. 6 Northeastern Section of the AUA — 2009 Annual Meeting S C H E D U L E - AT- A - G L A N C E Thursd ay, O ct obe r 8 , 20 0 9 Plenary Marquette/Jolliet Time Mackenzie Duluth Hochelaga 1-6 7 a.m. 7:30 - 9:45 a.m. 8 a.m. Plenary I: ED after Radical Prostatectomy - Francesco Montorsi, Gerald Brock and Panel Locally Advanced & Metastatic RRC - John Fitzpatrick, Pierre Karakiewicz and Panel 9 a.m. 9:45 - 10:15 a.m. Break 10 a.m. 11 a.m. 10:15 a.m. - Noon 10:15 a.m. - Noon Moderated Poster Session I Moderated Poster Session II Postate Cancer Basic Research Noon - 1:30 p.m. Noon Sneak Peek Luncheon Exhibit Hall 1 p.m. 1:30 - 2:45 p.m. Plenary II: Testosterone Supplementation and Its Risks Panel Exhibit Hall Open Prostatitis: A phoenix Rising from the Ashes - J. Curtis Nickel and Panel Hoch 1-6, Saguenay & St. Maurice 2 p.m. 1:30 - 3:30 p.m. 2:45 - 3:15 p.m. Break in Exhibit Hall 3 p.m. 4 p.m. 3:15 - 5 p.m. 3:15 - 5 p.m. Moderated Poster Session III Moderated Poster Session IV Robotics, Endoscopy, and Laparoscopy Bladder Cancer 5 p.m. 5:30 - 6:30 p.m. Exhibit Hall Grand Opening/Welcome Reception 6 p.m. 7 p.m. 7 - 9 p.m. Networking Reception (St. Laurent) 8 p.m. Registration Open: 7 a.m. - 5 p.m. Speaker Ready Room Open: 7 a.m. - 6 p.m. (Saint-Charles Room) Spouse Lounge Open: 7 - 9 a.m. (Suite 1742-John Lennon/Yoko Ono Suite) Events Plenary Exhibit Hall Poster Sessions Breaks Meetings/Nursing Program Industry Supported Breakfast 7 S C H E D U L E - AT- A - G L A N C E Frid ay, Oc t ob e r 9 , 20 0 9 Time/ Room Plenary Marquette/Jolliet Mackenzie 6 - 7:30 a.m. Industry Supported Breakfast - The Post Prostatectomy Bridge: Tissue Preservation after Radical Pelvic Surgery, Suported by Vivus, Inc. 6 a.m. 7 a.m. Richelieu 7:45 - 8:45 a.m. Plenary Session III: Section Stars 9 a.m. 8:45 - 9:45 a.m. Plenary Session IV: Prostate Cancer Screening Eric A. Klein, Francesco Montorsi and Panel 9:45 - 10:15 a.m. Break in Exhibit Hall 10 a.m. 11 a.m. Noon 2 p.m. 66:30 - 8 a.m. 5K Run for Residents 7:30 - 7:45 a.m. Best-of-Posters (from Thursday sessions) 8 a.m. 1 p.m. Saint Laurent/Gatineau Duluth 10:15 a.m. - Noon 10:15 a.m. - Noon Moderated Poster Session V Moderated Poster Session VI Pediatric Urology Oncology 9:30 a.m. - 1:30 p.m. Exhibit Hall Open Hoch 1-6, Saguenay & St. Maurice 7:30 a.m. - 4 p.m. Nursing Program (See page 30) Noon - 1:15 p.m. Lunch in Exhibit Hall 1:15 - 2:15 p.m. Plenary Session V: Prostate Cancer Chemoprevention - Eric A. Klein and Panel 2:15 - 3:15 p.m. AUA Course of Choice Interstitial Cystitis/Painful Bladder Syndrome and Related Conditions: Practical Management Strategies Robert Moldwin 3:15 - 3:30 p.m. PM Break 3 p.m. 5 p.m. 3:30 - 5 p.m. Moderated Poster Session VII 3:30 - 5 p.m. Moderated Poster Session VIII 5:30 - 6:30 p.m. General Urology Kidney Cancer Residents Reception 7 p.m. 7 - 10 p.m. Fun Night at Cirque Éloize 10 p.m. 8 Events Plenary Exhibit Hall Poster Sessions Breaks Meetings/Nursing Program Industry Supported Breakfast Northeastern Section of the AUA — 2009 Annual Meeting S C H E D U L E - AT- A - G L A N C E S atu rday, Oc tober 10, 20 0 9 Plenary Marquette/Jolliet Time Richelieu Harricana 6 - 7:30 a.m. Industry Breakfast Program – Revisiting Testosterone Levels Achieved with Androgen Ablation: What is Optimum Suppression? 6 a.m. Supported by Ferring Pharmaceuticals 7 a.m. 8 a.m. 7:30 - 8:30 a.m. 7:30 - 8:30 a.m. Residents Breakfast - How to Select a Urology Fellowship Program Business Meeting Shahrokh Shariat 8:30 - 8:45 a.m. Best-of-Posters (from Friday sessions) 8:45 - 9:30 a.m. Slotkin Lecture Sir Philip Ransley 9 a.m. 9:30 - 10:15 a.m. Plenary Session VI: Androgen Deprivation Therapy - Edward Messing, Pierre Karakiewicz and Panel 10 a.m. 10:15 - 10:45 a.m. Break in Exhibit Hall 10:45 a.m. - 11:20 p.m. Plenary VII: Pediatric Urology Sir Philip Ransley 11 a.m. 11:20 a.m. - Noon Stress Urinary Incontinence and Unstable Bladder - Martine Jolivet-Tremblay and Panel Noon - Meeting adjourns, box lunches available Noon 12:30 p.m. Tennis 12:30 p.m. Tour of Old Montréal 6:30 p.m. 6:30 - 7 p.m. President’s Reception 10 p.m. 7 - 10 p.m. President’s Banquet Events Plenary Exhibit Hall Poster Sessions Breaks Meetings/Nursing Program Industry Supported Breakfast Speaker Ready Room Saint Charles Room Hours of Availability: Thursday, October 8: 7 a.m. – 6 p.m. Friday, October 9: 7 a.m. – 6 p.m. Saturday, October 10: 7 a.m. – Noon 9 NORTH EASTERN S ECTION BOARD OF DI RECTORS 2008-2009 President Anne-Marie Houle, MD Montreal, Quebec President-Elect Joel B. Nelson, MD Pittsburgh, Pennsylvania Past President James W. L. Wilson, MD Kingston, Ontario Secretary Edward M. Messing, MD Rochester, New York Treasurer Hassan Razvi, MD London, Ontario Historian Jack Sales, MD Grand Bend, Ontario Representatives Young Urologist Members Canada J. Paul Whelan, MD Hamilton, Ontario New York Imad S. Nsouli, MD Syracuse, New York Pennsylvania Ronald L. Hrebinko, MD Pittsburgh, Pennsylvania At-Large - Canada Armen G. Aprekian, MD Montreal, Quebec At-Large - US Badar Mian, MD Albany, New York Canada Kenneth T. Pace, MD Toronto, Ontario United States Timothy D. Averch, MD Pittsburgh, Pennsylvania AUA Board of Directors Kevin Pranikoff, MD Eggertsville, New York 2008-2009 N S-AUA COM M ITTEES Arrangements Committee Diego Barrieras, MD Serge Carrier, MD Julie Franc Guimond, MD, Co-Chair Paul Perrotte, MD, Co-Chair Health Policy Committee Ronald Paul Kaufman, Jr., MD Robert Alan Mevorach, MD Allan Beatteay Patrick , MD J. Paul Whelan, MD, Chair Awards Committee Anne-Marie Houle, MD Kevin Pranikoff , MD James W.L. Wilson, MD, Chair Investment Committee Mark F. Bellinger, MD Joseph L. Chin, MD Anne-Marie Houle, MD Hassan Razvi, MD, Treasurer, Chair Bylaws Committee Gabriel P. Haas, MD Ron Kodama, MD Edward M. Messing, MD, Chair Development Committee David A. Corral, MD Joseph M. Greco, MD, Co-Chair David B. Patrick, MD J. Paul Whelan, MD, Co-Chair Judicial Committee R. Brewer Auld, MD Gabriel P. Haas, MD, Chair Kevin Pranikoff , MD Program Committee Serge Carrier, MD Peter Chan, MD Pierre Karakiewicz, MD, Chair Bruno Laroche, MD Armondo Lorenzo, MD Dawn McLellan, MD Robert Nam, MD D. Robert Siemens, MD Martine Jolivet Tremblay, MD Alexandre Zlotta, MD Scholarship Committee Darius Jehan Bagli, MD Erdal Erturk, MD Jodi K. Maranchie, MD Badar Munir Mian, MD, Chair Nominating Committee Gabriel P. Haas, MD Barry Kogan, MD William Hulbert, MD Dawn MacLellan, MD James W.L. Wilson, MD, Chair 10 Northeastern Section of the AUA — 2009 Annual Meeting NORTH EASTERN S ECTION RES EARCH AN D EDUCATION FU N D The purpose of the NS-AUA Foundation is to operate exclusively for educational, scientific and charitable purposes, including, but not by way of limitation, to foster, support and conduct education (including education of the general public) and research in the field of urology. The NS-AUA started funding research in 1995 through a grant from Searle Canada and Searle USA. A Research and Education Fund was established to assure the membership of the NS-AUA continuing excellence in research and educational activity within the Section. The NS-AUA Scholarship Program was established in 1998 to provide financial scholarships to support research and educational projects. The Section offers up to two scholarship awards annually. These Young Investigator Awards provide financial assistance to a researcher in basic or clinical sciences related to urology, and to acquiring, developing or improving his or her knowledge and skills in a specific aspect of the specialty. In all, 19 researchers have been awarded research scholarships. Through the generosity of our Section members and corporate supporters, the Research and Education Fund continues to grow. We gratefully acknowledge and thank: Abbott Cook (Canada) Inc. Novartis Oncology Abbott – Canada Cook Urological Incorporated Novartis Pharmaceuticals Corporation Amgen Inc. Endo Pharmaceuticals NS-AUA Members Astellas Pharma US Inc. Flarsheim/Mallinckrodt Olympus ACMI AstraZeneca Canada Inc. GlaxoSmithKline Ortho-McNeil AstraZeneca Pharmaceuticals LP Healthtronics, Inc. Pfizer Inc Bayer Healthcare Pharmaceuticals Janssen-Ortho Inc. Pfizer Canada Boehringer Ingelheim – Canada Karl Storz Endoscopy – America, Inc. Praecis Pharmaceuticals Incorporated Boehringer Ingelheim Pharmaceuticals, Inc. Karl Storz Endoscopy Canada Ltd. Procter & Gamble Pharmaceuticals Boston Scientific Lilly USA, LLC sanofi-aventis Group Bristol-Myers Squibb Merck US Human Health Schering Oncology/Biotech CR Bard Merck Frosst Canada Ltd. The Northeastern Section thanks the following companies for providing educational grants in support of the 2009 Annual Meeting: Allergan Genentech BioOncology Astellas Pharma US, Inc. Ortho Women’s Health and Urology Dendreon Corporation Pfizer Inc Endo Pharmaceuticals sanofi-aventis U.S. Ethicon Women’s Health and Urology And the following companies for their general support of the Annual Meeting: Abbott Oncology Pfizer Inc Astellas Pharma US, Inc. Pfizer Canada, Inc. AstraZeneca Canada Inc. sanofi-aventis Canada, Inc. Eli Lilly Canada, Inc. VIVUS, Inc. Ferring Pharmaceuticals Watson Pharmaceuticals, Inc. Olympus 11 PAST PRES I DENTS AN D M EETI NG VEN U ES YEAR 1948-1949 1949-1950 1950-1951 1951-1952 1952-1953 1953-1954 1954-1955 1955-1956 1956-1957 1957-1958 1958-1959 1959-1960 1960-1961 1961-1962 1962-1963 1963-1964 1964-1965 1965-1966 1966-1967 1967-1968 1968-1969 1969-1970 1970-1971 1971-1972 1972-1973 1973-1974 1974-1975 1975-1976 1976-1977 1977-1978 1978-1979 1979-1980 1980-1981 1981-1982 1982-1983 1983-1984 1984-1985 1985-1986 1987-1988 1988-1989 1989-1989 1990-1991 1991-1992 1992-1993 1993-1994 1994-1995 1995-1996 1996-1997 1997-1998 1998-1999 1999-2000 2000-2001 2001-2002 2002-2003 2003-2004 2004-2005 2005-2006 2006-2007 2007-2008 *Deceased PRESIDENT James C. McClelland* A. Lawrence Parlow* William J. Kennedy* William A. Barrett* David R. Mitchell* Albert M. Crance* Walter J. Hayward* William Baurys* Allan B. Hawthorne* William A. Milner* S. H. Johnson III* Frances O. Harbach* J. Victor Berry* John S. Fitzgerald* Hollister W. Lyon* John A. Benjamin* Arthur Bedard* Michael G. O'Brien* William B. Garlick* William E. Collins* David W. Kline* Hobart L. Boyd* Charles L. Robson* Charles C. Altman* William J. Staubitz* Lloyd N. McAninch* Stuart E. Price* Peter O. Crassweller Otto M. Lilien* John F. Rose Jr. Andrew W. Bruce Abraham A.T. Cockett Alan H. Irvine* Andre Vallieres Leo M. King Irwin N. Frank Martin Barkin Pierre E. Bertrand David H. Barnhouse Grant A. Farrow Jack L. Sales Marcus L. Shoobe Said A. Awad Alan H. Bennett Normand Sullivan* Anthony V. Passaretti* Mostafa M. Elhilali Ronald Rabinowitz David B. Patrick Alvaro Morales Kevin Pranikoff R. Brewer Auld Datta G. Wagle Joseph L. Chin Mark F. Bellinger John D. Denstedt Gabriel P. Haas Barry A. Kogan James W. L. Wilson PRESIDENT’S HOME Toronto, ON Rochester, NY Gloversville, NY Pittsburgh, PA Toronto, ON Geneva, NY Jamestown, NY Sayre, PA Montreal, QC Albany, NY Pittsburgh, PA Syracuse, NY Ottawa, ON Utica, NY Punxsutawney, PA Rochester, NY Quebec City, QC Scranton, PA Albany, NY Ottawa, ON Greenville, PA Rochester, NY Toronto, ON Pittsburgh, PA Buffalo, NY London, ON Pittsburgh, PA Toronto, ON Syracuse, NY Danville, PA Kingston, ON Rochester, NY Ottawa, ON Quebec City, QC McKeesport, PA Rochester, NY Toronto, ON Quebec City, QC Pittsburgh, PA Toronto, ON London, ON Albany, NY Halifax, NS Albany, NY St. Anne de Sorel, QC Albany, NY Montreal, QC Rochester, NY Beaver, PA Kingston, ON Buffalo, NY Halifax, NS Williamsville, NY London, ON Pittsburgh, PA London, ON Syracuse, NY Albany, NY Kingston, ON ANNUAL MEETING VENUE Bigwin Inn, Huntsville, ON The Sagamore, Lake George, NY Lake Placid Club, Lake Placid, NY Hamilton Princess, Bermuda Shawnee Inn, Shawnee on Delaware, PA Chateau Frontenac, Quebec City, QC Lake Placid Club, Lake Placid, NY Equinox House, Manchester, VT Whiteface Inn, Lake Placid, NY Equinox House, Manchester, VT Seignory Club, Montebello, QC Bedford Springs Resort, Harrisburg, PA Equinox House, Manchester, VT Grossinger's, Liberty, NY Chateau Frontenac, Quebec City, QC Pocono Manor, Pocono Manor, PA Otesaga Hotel, Cooperstown, NY Shawnee Inn, Shawnee on Delaware, PA The Sagamore, Lake George, NY Whiteface Inn, Lake Placid, NY Whiteface Inn, Lake Placid, NY Hershey Hotel, Hershey, PA King's Inn, Freeport, Grand Bahamas Sheraton Hyannis, Cape Cod, MA Inn on the Park, Toronto, ON Mountain View House, Whitefield, NH Buck Hill Inn, Buck Hill Falls, PA The Homestead, Hot Springs, VA Chateau Frontenac, Quebec City, QC Lake Placid Club, Lake Placid, NY Hotel Bonaventure, Montreal, QC Copley Plaza Westin Hotel, Boston, MA Chateau Laurier Hotel, Ottawa, ON The Nevele Country Club, Ellenburg, NY Chateau Frontenac, Quebec City, QC Albany Hilton, Albany, NY The Copley Plaza Westin Hotel, Boston, MA The Four Seasons Hotel, Toronto, ON The Breakers, Palm Beach, FL Hamilton Princess, Bermuda Chateau Champlain, Montreal, QC Halifax Sheraton, Halifax, NS Colonial Williamsburg, VA Toronto Hilton, Toronto, ON El San Juan Hotel, San Juan, PR The Sagamore, Lake George, NY Cairo Marriott Hotel, Cairo, Egypt Buffalo Hilton, Buffalo, NY Wigwam Resort, Phoenix, AZ Royal York Hotel, Toronto, ON The Westin Hotel, Pittsburgh, PA Boca Raton Resort, Boca Raton, FL Fairmont Mt. Tremblant, Mount Tremblant, QC Halifax World Trade Centre, Halifax, NS Westin Hotel, Savannah, GA Southampton Princess, Bermuda Westin Hotel, Ottawa, ON Hyatt Regency, Rochester, NY Hyatt Tamaya, Santa Ana Pueblo, NM 12 Northeastern Section of the AUA — 2009 Annual Meeting DR. G EORG E E. S LOTKI N Excerpt from the Waterways chapter: “No history of the Northeastern Section is complete without a short biography of this indefatigable urologist. His later work with E.A. Mercer, ‘Case of epispadias with a double urethra,’ was published in The Journal of Urology in 1953. Dr. George E. Slotkin (1890-1971) was born in New York City but soon moved with his parents to Buffalo, NY, where he spent his professional career. We acknowledge him today as a founder, the first benefactor, and the first historian of the NS, but there is more to his story. Obviously, this change in his work reflects the change in urology from its early focus on genitourinary disease to its present focus as a surgical specialty. Dr. Slotkin was named Clinical Professor of Urology Emeritus in 1954 by the University of Buffalo Medical School and continued his private practice until 1964. After retirement, he continued to write, contributing a fascinating chapter about the history of the Northeastern Section to History of Urology. It is a priceless, logical record of carefully researched facts. If one were to hold up a mirror to the changing face of urology in the first half of the 20th century, it would be well reflected with an image of George E. Slotkin. A graduate of the University of Buffalo Medical School, Dr. Slotkin did postgraduate work at the New York City Post Graduate Hospital, the University of Vienna, and the University of Budapest. In 1918, he became a clinical professor of urology at the University of Buffalo. During the late 1940s, his clinical interest was tuberculosis of the urinary tract, which he treated with chalamagoric acid. Even though results of his work in this area remain inconclusive, other fruits of his career do not. Friends and colleagues of his time were fond of saying, ‘George Slotkin has three loves: urology, his wife Helene, and his Rolls Royce...not necessarily in that order!’ His early work, ‘Nephroptosis, a resurrected disease,’ was published in The Urologic and Cutaneous Review in 1938. His obituary notice implies that he may have been the first American invited to join the Canadian Urological Association. Dr. and Mrs. Slotkin did not have any children; his estate included a generous bequest to the Northeastern Section to provide funding for invited guest speakers at our annual meetings.” Meyer, Robert, MD and Margaret, “History of the Northeastern Section of the American Urological Association: Waterways.” The American Urological Association Centennial History 1902 – 2002. Ed. Lawrence Jones, MD and Paul Peters, MD Baltimore: The American Urological Association, 2001. 585-642. G EORG E E. S LOTKI N LECTU RERS 1975 Prof. Willie L. M. Gregoir, Brussels, Belgium 1994 Carl Olsson, MD, Larchmont, New York 1976 J. Engelbert Dunphy, MD, San Francisco, California 1995 Peter Scardino, MD, Houston, Texas 1977 B. E. Christopher Nordin, MD, Leeds, England 1996 Bernard M. Churchill, MD, Los Angeles, California 1978 Donald Smith, MD, Piscataway, New Jersey 1997 Peter R. Carroll, MD, San Francisco, California 1979 J. Genest, MD, Montreal, Quebec 1998 Joyce Lisa Tenover, MD, Atlanta, Georgia 1980 Joseph J. Kaufman, MD, Los Angeles, California 1999 Richard D. Williams, MD, Iowa City, Iowa 1981 Roger C. B. Pugh, MD, London, England 2000 Gerry G. Blaivas, MD, New York, New York 1982 Donald S. Coffey, MD, Baltimore, Maryland 2001 Alvaro Morales, MD, Kingston, Ontario 1983 Martin I. Resnick, MD, Cleveland, Ohio 2002 Edson Pontes, MD, Detroit, Michigan 1984 Willet F Whitmore Jr., MD, New York, New York 2003 Gerald L. Andriole, MD, St. Louis, Missouri 1985 Peter Scardino, MD, Houston, Texas 2004 Mustafa Elhilali, MD, Montreal, Quebec 1986 William Fair, MD, New York, New York 2005 Margaret Sue Pearle, MD, Dallas, Texas 1987 John Duckett, MD, Philadelphia, Pennsylvania 2006 Mani Menon, MD, Detroit, Michigan 1988 Anthony R. Mundy, MD, London, England 2007 Darius Jehan Bagli, MD, Toronto, Ontario 1989 Robert Jeffs, MD, Baltimore, Maryland 2008 S. Larry Goldenberg, MD, Vancouver, British Columbia 1990 Charles J. Devine, MD, Norfolk, Virginia 2009 Sir Philip G. Ransley, MD, London, United Kingdom 1991 Thomas Stamey, MD, Stanford, California 1992 Michael E. Mitchell, MD, Seattle, Washington 1993 Donald S. Coffey, MD, Baltimore, Maryland 13 2009 Invited Guest Speakers Gerald B. Brock, MD hances the learning of clinical aspects of surgical training. Professor, Department of Surgery For the years to come, Dr. Jolivet will be active coordinating clerkship common efforts to provide the highest quality standards of excellence in health services, to be eligible for the habilitation standards supported by the accreditation process for public health in North America. St. Joseph’s Health Centre London, ON, Canada Gerald Brock, MD, is Professor, Department of Surgery, Division of Urology, at St. Joseph’s Health Centre in London, Ontario. He completed his Medical and Urology Degrees at McGill University in Montreal and subsequently did a two year fellowship in neurourology at the University of California, San Francisco. He currently runs a large tertiary care erectile dysfunction clinic at St. Joseph’s Health Care, where he sees between 2,000 to 2,500 new consults annually. In addition to his responsibilities as resident program director, he runs a productive basic animal research lab evaluating the impact of disease on erectile mechanisms. Dr. Brock is an active participant in professional associations, previous chair of the Canadian Male Sexual Health Council (affiliate of the Canadian Urology Association - CUA), past chair of the Guidelines Committee of the CUA. He currently serves as the administrative chair of the CUA Scholarship Fund, treasurer of the Canadian Urology Research Consortium and serves as chair of the Scientific Research Committee of the Canadian Society for the Study of the Aging Male. Dr. Brock is the author of over 130 peer reviewed publications, 25 book chapters as well as numerous abstracts. Over the past decade he has been invited to speak across Canada, the United States, Europe, Australia and Asia. Dr. Brock has been awarded over 20 research prizes for his clinical and basic research endeavours evaluating the impact of disease states on erectile and ejaculatory mechanisms. Dr. Brock’s work in urology and erectile dysfunction is acknowledged by his role as Editor-in-Chief of Chronicles of Urology and Sexual Health, CME Section Editor of the Journal of Sexual Medicine, Andrology Section Editor of the CUA Journal. Martine Jolivet-Tremblay, MD Eric A. Klein, MD Chairman, Glickman Urological and Kidney Institute Professor of Surgery, Cleveland Clinic Lerner College of Medicine Cleveland, OH Eric A. Klein, MD is professor of surgery in the Lerner College of Medicine and interim chair of the Glickman Urological and Kidney Institute of the Cleveland Clinic. Following undergraduate training at Johns Hopkins University, he was a cum laude graduate of the University of Pittsburgh School of Medicine. He subsequently completed residency training in urology at the Cleveland Clinic and a fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center. He joined the staff of the Cleveland Clinic in 1989 and currently serves as chair of the Glickman Urological and Kidney Institute. Dr. Klein’s clinical and research interests cover all of urologic oncology and particularly clinical trials for localized and locally advanced prostate cancer. He serves as the chair of the Localized Prostate Cancer Committee of the Southwest Oncology Group and is the National Study Coordinator for the NCI-sponsored Selenium and Vitamin E Cancer Prevention Trial (SELECT). Dr. Klein has contributed more than 300 papers to the scientific literature, authored or edited seven books on urologic malignancies, and serves as the Editor-in-Chief of Urology. He has delivered more than 200 invited scientific lectures including eight named lectureships, and has served as a Visiting Professor at more than 45 institutions around the world. Dr. Klein is a codiscoverer of XMRV, a novel human virus found in men genetically predisposed to prostate cancer. Professor, Department of Surgery University of Montreal John M. Fitzpatrick, MD Montreal, QC, Canada Professor Mater Misericordiae Hospital 14 Dr. Jolivet has been a urologist for ten years and works at the I’Hôpital Saint-Luc du CHUM, as well as an assistant professor in surgery department at the Université de Montréal. Within the last few years, Dr. Jolivet has also worked as the clerkship director for the MD program. Her postgraduate training was in neuro-urology in Toronto. Moreover, she is the recipient of the 2007's Wilbrod-Bonin Prize from the University of Montreal. Convinced of the importance of clinical education in medicine, Dr. Jolivet believes in a new approach in education that en- Dublin, Ireland John Fitzpatrick, MD, was born and educated in Dublin. He qualified as a doctor in 1971 and become fellow of the Royal College of Surgeons in Ireland in 1975. He received his Masters degree in 1976. He is also a fellow of the Royal College of Surgeons of England and of Glasgow. Between 1977 and 1981, Professor Fitzpatrick trained in the St. Northeastern Section of the AUA — 2009 Annual Meeting Peters Hospitals and the Institute of Urology in London. In 1981, Professor Fitzpatrick returned to Dublin as Consultant Urologist and Senior Lecturer in Urology in the Meath and St. James' Hospitals and Trinity College Dublin. In 1986, Professor Fitzpatrick was appointed Professor and Chairman of the Department of Surgery in the Mater Misericordiae Hospital and University College Dublin. Professor Fitzpatrick has performed 45 visiting professorships in the United States and other countries throughout the world. He has also given 167 guest lectures throughout the world. He has produced 260 peer reviewed publications, 74 book chapters, has edited six journal editions, and published 12 books. Professor Fitzpatrick is on the editorial board of 25 journals, and is editor-in-chief of the BJU International. He is president of the Irish Society Urology and is immediate past president of the British Association of Urological Surgeons. He is a member of the Board of Trustees of the British Urological Foundation and is chair of the Scientific Committee of that Foundation. He is an honorary fellow of the College of Urologists of South Africa and an honorary member of the British Association of Urological Surgeons and of the American Urological Association as well as an Honorary member of the Urological Societies of Australasia, South Africa, Germany, Netherlands, Hungary, Argentina, Greece, and Georgia. Edward M. Messing, MD W.W. Scott Professor Chairman, Dept. of Urology Professor of Oncology and Pathology University of Rochester School of Medicine and Dentistry Rochester, NY Dr. Messing received his MD degree from New York University in 1972, completed his surgery training at NYU-Bellevue Hospital in New York 1972-1974 and his Urology Residency at Stanford University 1974-1978. After two years on the faculty at Tulane University, he completed a fellowship in urologic oncology at UCLA in 1982. He was on the faculty of the Division of Urology at the University of Wisconsin from 1982-1995, being director of their Urologic Oncology Program for the last 10 years. He assumed his current position at the University of Rochester School of Medicine and Dentistry in September 1995. Dr. Messing is a renowned expert in the diagnosis and treatment of cancers of the bladder, prostate, kidney and other genitourinary organs. He carries on extensive research in the basic biology of bladder and prostate cancers, and has been the principal investigator on numerous clinical studies for the detection, prevention and treatment of genitourinary cancers. Among other activities, he has designed, conducted and reported on two large randomized phase III trials germane to his presentations at the NS-AUA Meeting: The use of adjuvant interferon alpha for completely resected local/regionally extensive renal cell cancer (J Clin Oncol 21:1214-1222, 2003); the use of adjuvant ADT for N+ prostate cancer following radical prostatectomy (EST 3886; NEJM 341:24;1781-1788, 1999; Lancet Oncology, 7(6):472-9;2006). Robert M. Moldwin, MD, FACS Associate Professor, The Smith Institute for Urology Long Island Jewish Medical Center Long Island, NY Robert M. Moldwin, MD is associate professor of Clinical Urology at Hofstra University School of Medicine and director of the Pelvic Pain Center at The Smith Institute for Urology of the North-Shore–Long Island Jewish Healthcare System. Dr. Moldwin’s career spans 18 years during which time he has functioned as a clinician, researcher, patient advocate and media consultant, primarily focusing upon topics related to urologic infectious/ inflammatory disease and pelvic pain syndromes. He travels extensively as a national and international lecturer. Media hits include: CNN, You Tube, CBS News, Cosmopolitan, Woman’s Day, Newsday, Oxygen, Men’s Health, Self Magazine and Ladies Home Journal, among others. Dr. Moldwin’s primary research interests rest with urological pain syndromes such as Interstitial cystitis/painful bladder syndrome (IC/PBS) and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), conditions that are considered present in over four million people in the United States. He has published extensively in peer-reviewed journals. ”The Interstitial Cystitis Survival Guide,” by Dr. Moldwin, was the first physician-written book exclusively related to interstitial cystitis for healthcare professionals and patients. Dr. Moldwin’s research has been published in Cancer, Contemporary Urology, Current Urology Reports, Women’s Healthcare, The Canadian Journal of Urology, The British Medical Journal, The Journal of Urology® and Urology. He is a reviewer for medical journals including The Journal of Urology®, Urology, The Journal of Endourology, The Medical Letter, and The Journal of Pelvic Surgery. Dr. Moldwin earned his undergraduate degree at Adelphi University in Garden City, NY, and his medical degree at the University of Chicago, Pritzker School of Medicine in Chicago, IL. He completed residencies in general surgery and urology at the Long Island Jewish Medical Center. He also served as a Valentine fellow, studying infectious and inflammatory urological diseases in the Department of Urology at Thomas Jefferson Medical College in Philadelphia, PA Dr. Moldwin currently serves on multiple medical advisory boards including the Interstitial Cystitis Association. He is a member of The American Urological Association, The American Association of Clinical Urologists, The International Association for the Study of Pain, and The Society for Urodynamics and Female Urology. This year, Dr. Moldwin begins his tenure as President of the Society for Infection and Inflammation in Urology. 15 Francesco Montorsi, MD Professor of Urology, Department of Urology University Vita-Salute San Raffaele Milan, Italy Francesco Montorsi, MD, is professor of urology at University VitaSalute San Raffaele, Department of Urology, in Milan, Italy. He is also Head of the Sexual Medicine Center and an attending urologist, Department of Urology, at San Raffaele Hospital in Milan. Prof. Montorsi received his medical degree from the University of Milan School of Medicine, where he also completed a residency in urology. In addition, he completed a residency in andrology at the University of Pisa School of Medicine. Prof. Montorsi’s major research interests have included several urological areas with a specific focus on pathophysiology, diagnosis and management of sexual dysfunctions, prostate cancer and benign prostatic hyperplasia. As a widely published author, Prof. Montorsi has co-authored more than 400 peer reviewed journal articles and several book chapters. His most recent contributions to the literature have been on the management, treatment, and pathophysiology of male and female sexual dysfunctions, prostate cancer and benign prostatic hyperplasia. His articles have been published in many prestigious journals including The Lancet, Journal of Clinical Oncology, European Heart Journal, Diabetes Care, European Urology, International Journal of Cancer, European Journal of Cancer, Journal of Sexual Medicine, Drugs, Journal of Urology®, British Journal of Urology International, Urology, The International Journal of Impotence Research, Surgery, Hormones and Behavior and Current Opinion of Urology. He is editor-in-chief for European Urology (IF: 6.512) and for European Urology Supplements (IF: 1.711). He is a reviewer for The Lancet, JAMA, European Urology, The Journal of Urology®, Urology, Urological Research, British Journal of Urology International, International Journal of Impotence Research, World Journal of Urology and The Journal of Sexual Medicine. Prof. Montorsi holds positions in several international professional organizations including past-president of the European Society for Sexual Medicine. Prof. Montorsi has been designated as chair of the 2009 International Consultation on Sexual Dysfunctions sponsored by the WHO. J. Curtis Nickel MD, FRCSC Professor, Department of Urology, Queen’s University, CIHR Tier 1 Canada Research Chair in Urologic Pain and Inflammation Staff Urologist, Department of Urology, Kingston General Hospital 16 Kingston, Ontario, Canada ber of the Department of Urology at Queen’s University since 1984 (promoted to Professor in 1994). Dr. Nickel’s research has been in the fields of inflammatory diseases of the urinary tract and benign diseases of the prostate gland. He has written over 400 scientific papers, reviews, chapters and books on these subjects. He has given invited lectures in over forty countries. His work in prostatitis, interstitial cystitis and BPH has led to new appreciation of these conditions, provided epidemiological support for their importance, updated definitions and classifications, validated outcome parameters and his multiple clinical treatment trials have provided an evidence based foundation for therapy. He has served on the examination committee and as an examiner for the American Board of Urology and is presently on the examination committee of the Royal College of Physicians and Surgeons of Canada. He has been a member of the American Association of Genito-urinary Surgeons since 2004. He was recently appointed as the CIHR Canada Research Chair in Urologic Pain and Inflammation. Sir Philip G. Ransley, M.A., M.B., B.Chir., FRCS, FRCS (Ed., Hon.), FAAP (Hon.). Consultant, Pediatric Urologist London, England Mr. Ransley graduated from the University of Cambridge with clinical training at Guy’s Hospital and proceeded to Fellowship of the Royal College of Surgeons of England in 1971. He trained in general surgery and urology before specialising in pediatric urology. He was trained by Sir David Innes Williams and appointed to the staff of Great Ormond Street Children’s Hospital in 1977, where he worked until his retirement in 2004. He held additional appointments at the St Peters’ Hospitals (Institute of Urology) and latterly at Guy’s Hospital. He held an academic appointment with University College London as senior lecturer in pediatric urology at the Institute of Child Health. He served on the Board of the European Society for Paediatric Urology and as it’s President from 1996-2000. He has been made an honorary fellow of the American Academy of Pediatrics and recently received an honorary fellowship from the Royal College of Surgeons of Edinburgh. Since his retirement Mr. Ransley has been active in several institutions around the world, but in particular at the Sindh Institute of Urology and Transplantation in Karachi, Pakistan, where he has established a thriving pediatric urology unit, providing free treatment for a wide variety of complex pediatric urological disorders from all over Pakistan. He has a lifetime’s interest in astronomy and for the last 20 years has been chasing total solar eclipses around the globe. He currently observes the night sky from the mountains around his home at Lake Como in Italy. J. Curtis Nickel, MD, completed his undergraduate, surgical, urological and research training in Canada. He has been a mem- Northeastern Section of the AUA — 2009 Annual Meeting Breakaway Shahrokh F. Shariat, MD Fellow, Division of Urology Memorial Sloan Kettering Cancer Center and take a shot on winning a $150 Visa gift card! New York, NY Shahrokh F. Shariat is a fellow at the Division of Urology at Memorial Sloan Kettering Cancer Center, New York, NY. He is a member of various academic societies, national committees, and editorial boards. His published scientific papers focus on translational research in urologic oncology, molecular mechanisms, markers, early detection, natural history, treatment, translational and outcomes research as well as gene and vaccine therapies. He has published over 250 articles in both national and international journals and a dozen book chapters. He is currently spearheading several collaborative groups and prospective clinical trials; he has had continuous NIH funding. Visit the NS-AUA hockey game on the Exhibit Floor during Exhibit Hall hours. Publication of Abstracts – 2009 The Board of Directors of the NS-AUA is pleased to announce that all accepted abstracts of the 2009 annual meeting have been published in a supplement to the October issue of the Canadian Urological Association Journal (CUAJ). A copy of this issue and supplement of CUAJ will be distributed with this program book. On behalf of the authors, the Executive Officers extend its sincerest thanks and appreciation to the Canadian Urological Association Journal (CUAJ). CUAJ is owned and officially endorsed by the Canadian Urological Association. CUAJ is a bimonthly publication and is searchable on PubMed, with full-text articles on PubMed Central and on the newly created CUAJ website (www.cuaj.ca). CUAJ is also covered in the Science Citation Index Expanded (also known as SciSearch) and the Journal Citation Reports/Science Edition provided by Thomson Reuters. Journal editors welcome your manuscripts for review and consideration for publication. For additional information on submitting manuscripts or subscription information, contact: Josephine Sciortino Managing Editor, CUAJ 1155 University, Suite 1303 Montréal, QC, Canada H3B 3A7 Phone: +1 514 395-0376, ext. 40 Fax: +1 514 395-1664 E-mail: [email protected] Web site: www.cuaj.ca 17 Scientific Program *Subject to Change Paul Perrotte1, Pierre I. Karakiewicz1 THURSDAY, OCTOBER 8, 2009 7:30 a.m. Opening Session Anne-Marie Houle Northeastern Section President University of Montréal, Montréal, QC, Canada; Vita-Salute San Raffaele, Milan, Italy 1 2 11:12 a.m. Anton J. Bueschen American Urological Association President 7:45 – 9:45 a.m. 7:45 a.m. 7:50 a.m. Plenary I Lars Budäus1, Hendrik Isbarn2, Felix F. K. Chun3, Caludio Jeldres1, Sascha A. Ahyai3, Thomas Steuber2, Roman Heuer3, Mario Zacharias3, Thorsten Schlomm2, Georg Salomon2, Alexander Haese2, Hans Heinzer2, Hartwig Huland2, Markus Graefen2, Pierre I. Karakiewicz1 Welcome and Introduction Erectile Dysfunction (ED) after Radical Prostatectomy Francesco Montorsi, Università Vita Salute, Milan, Italy Gerald Brock, London, ON, Canada University of Montréal, Montréal, QC, Canada; Martiniclinic, Prostate Cancer Center HamburgEppendorf, Hamburg, Germany; 3University Hospital Hamburg-Eppendorf, Hamburg, Germany 1 Panel: Francois Benard and Serge Carrier Moderator: Paul Perrotte 8:40 a.m. 2 Locally Advanced and Metastatic RCC John Fitzpatrick 11:15 a.m. Panel: Paul Perrotte, Francois Patenaude, and Simon Tanguay Moderator: Pierre Karakiewicz 11 a.m. Break Concurrent Poster Sessions View Posters Welcome and Introduction Moderated Poster Session I: Prostate Cancer Moderators: Francesco Montorsi and Alexandre R. Zlotta P1. Pelvic Radiation in Patients with a Ross Bauer, William Conners, Badar Mian Stratton VA Medical Center, Albany, NY, United States. 11:18 a.m. University of Pittsburgh Medical Center, Pittsburgh, PA, United States 11:21 a.m. P2. Management of Prostate Cancer Sunnybrook HSC, Toronto, ON, Canada 11:24 a.m. Following Solid Organ Transplantation 1Roswell Park Cancer Institute, Buffalo, NY, United States; 2National Cancer Institute, Bethesda, MD, United States University of Pittsburgh School of Medicine, Pittsburgh, PA, United States P3. A Systematic Analysis of the Detrimental Effect of Orchiectomy on 12 Systemic Morbidities 11:27 a.m. Valerie Deslauriers1, Hendrik Isbarn1, Claudio Jeldres1, Giovanni Lughezzani1, Maxine Sun1, Philippe Arjane1, Hugues Widmer1, Daniel Pharand1, Francesco Montorsi2, Paul Perrotte1, Pierre I. Karakiewicz1 University of Montréal, Montréal, QC, Canada; Vita-Salute University, Milan, Italy 2 18 P4. A Systematic Analysis of the Detrimental Effect of Orchiectomy on Four Skeletal Morbidities Claudio Jeldres1, Umberto Capitanio1, Hendrik Isbarn1, Giovanni Lughezzani1, Shahrokh F. Shariat1, Maxine Sun1, Daniel Pharand1, Hugues Widmer1, Philippe Arjane1, Francesco Montorsi2, P10. High-Grade Prostatic Intraepithelial Neoplasia (HG-PIN) on Initial Prostate Biopsy Is Not a Risk Factor for Prostate Cancer at Repeat Biopsy Lars Budäus1, Christopher R. Porter2, Claudio Jeldres1, Kora Tang3, Sascha A. Ahyai4, Felix K. H. Chun4, Hendrik Isbarn3, Georg Salomon3, Thorsten Schlomm3, Alexander Haese3, Thomas Steuber3, Hans Heinzer3, Hartwig Huland3, Markus Graefen3, Pierre I. Karakiewicz1. 1 11:09 a.m. P9. Racial Differences in Risk Perception and Receipt of PSA Testing Willie Underwood III1, Vickie L. Shavers2, Richard P. Moser2 Jeff Larson, Jeffrey J. Tomaszewski, Marc C. Smaldone, Stephen V. Jackman 11:06 a.m. P8. Clinical Results of Long-Term Follow-up of a Large Active Surveillance Cohort Laurence Klotz, Adam Lam, Alex Mladenov, Gerard Morton, Andrew Loblaw David M. Berlach, Marylene Brodeur, DABR, Fabio Cury 11:03 a.m. P7. The Impact of Surgeon Fatigue on Performance of Open Radical Retropubic Prostatectomy Marc C. Smaldone, Jeffrey J. Tomaszewski, Joel B. Nelson Pelvic Kidney: No Longer Playing with Fire McGill University, Montréal, QC, Canada P6. National Patterns of Diagnosis and Treatment of Localized Prostate Cancer at Veterans Administration Medical Centers Mater Misericordial Hospital, Dublin, Ireland 9:45 – 10:15 a.m. 10:15 a.m. - Noon 10:15 – 10:45 a.m. 10:45 – 11 a.m. 11 a.m. – Noon P5. External Validation of a Postoperative Nomogram Predicting the Probability of Prostate Cancer Recurrence After Radical Prostatectomy 1University of Montréal, Montréal, QC, Canada; 2Virginia Mason Medical Center, Seattle, WA, United States; 3Martiniclinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany; 4University Hospital Hamburg-Eppendorf, Hamburg, Germany 11:30 a.m. P11. Unilateral Prostate Cancer Cannot Be Reliably and Accurately Diagnosed Northeastern Section of the AUA — 2009 Annual Meeting Prize-winning Essays LOOK FOR THIS ICON with Systematic 10 or More Core Biopsy 1 2 Maxine Sun1, Francesco Montorsi3, Paul Perrotte1, Pierre I. Karakiewicz1 1 Lars Budäus , Hendrik Isbarn , Claudio Jeldres , Sascha A. Ahyai3, Thorsten Schlomm2, Georg Salomon2, Hans Heinzer2, Thomas Steuber2, Alexander Haese2, Hartwig Huland2, Markus Graefen2, Felix K. H. Chun3, Pierre I. Karakiewicz1 1University of Montréal, Montréal, QC, Canada; 2Martiniclinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany; 3University Hospital HamburgEppendorf, Hamburg, Germany 11:33 a.m. 1University of Montréal, Montréal, QC, Canada; 2Lille University Hospital, Lille, France; 3Vita Salute University San Raffaele, Milan, Italy; 4Martiniclinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany 11:48 a.m. Jonah S. Marshall, Allison L. Cardin, Eric A. Singer, Andrew Tompkins, Edwin van Wijngaarden, Paul Winters, Ralph Brassachio, Dragan Golijanin, Edward M. Messing P12. Presence of Prostate Cancer at Saturation Biopsy Can Be Accurately Predicted Lars Budäus1, Sascha A. Ahyai2, Hendrik Isbarn3, Felix K. H. Chun2, Matthias Reichert2, Thomas Steuber3, Hans Heinzer3, Georg Salomon3, Paul Perrotte1, Hartwig Huland3, Markus Graefen3, Alexander Haese3, Pierre I. Karakiewicz1 1University of Montréal, Montréal, QC, Canada; 2University Hospital Hamburg-Eppendorf, Hamburg, Germany; 3Martiniclinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany 11:36 a.m. University of Rochester, Rochester, NY, United States 11:51 a.m. Noon 11 a.m. – Noon 11 a.m. P13. Are All Low-Risk Prostate Cancer Clay W. Mechlin1, Matt Tanner2, Badar Mian3, Ralph Buttyan2. Albany Medical Center, Albany, NY, United States; Ordway Research Center, Albany, NY, United States; 3Albany Medical Center, Stratton VA Medical Center, Albany, NY, United States 1 2 11:03 a.m. University of Montréal, Montréal, QC, Canada; 2Martiniclinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany; 3University Hospital Hamburg-Eppendorf, Hamburg, Germany 1 11:39 a.m. P14. Does Maximal Percent of Core Biopsy Positive for Prostate Cancer Correlate to Predictors of Disease Recurrence? University of Pittsburgh, Pittsburgh, PA, United States; William Beaumont, Royal Oak, MI, United States 1 2 11:06 a.m. P15. Comparison of Tertiary Center and Referred Prostate Biopsies: Impact of Re-Review on Gleason Score Accuracy University of Pittsburgh, Pittsburgh, PA, United States 11:09 a.m. Joice Rocha, Amina Zoubeidi, Fatima Zouanat, Lucie Hamel, PhD, Eleonora Scarlata, Armen Aprikian, Simone Chevalier Albany Medical College, Albany, NY, United States; Stratton VA Medical Center, Albany, NY, United States 1 2 McGill, Montréal, QC, Canada P16. Systematic Assessment of Total 11:12 a.m. Prostate Specific Antigen (PSA) and Percentage Free/Total PSA on the Rate of Biopsy Recommendation: A Population-Based Study 2 P21. Prostate Cancer Progression Through the Fer Kinase, a Potent Regulator of Androgen Receptor Signaling Michael A. Feuerstein1, Michael Hong1, Tipu Nazeer2, Hugh Fisher1, Ronald Kaufman, Jr.1, Badar M. Mian2 1 P20. Cannabinoid Receptors in Human Urothelial Carcinoma Ruthie Su, Vikas Tyagi, Brian Phillips, Pradeep Tyagi, Naoki Yoshimura University of Rochester, Rochester, NY, United States 11:45 a.m. P19. Effect of Neoplasia in the Urinary Tract on Urine Levels of CC Chemokines: A Cross-Sectional Study Bruce L. Jacobs1, Yoram Vodovotz1, Vikas Tyagi1, Derek Barclay1, Stephen V. Jackman1, Wendy W. Leng1, Pradeep Tyagi2 Matthew M. Lux, Tricia D. Greene, Erdal Erturk, Jean V. Joseph 11:42 a.m. Discussion Adjourn Moderated Poster Session II: Basic Research Moderators: Shahrokh Shariat and Jean-Baptiste Lattouf P18. Evaluation of Hedgehog Signaling in Human Transitional Carcinoma Cell Lines Patients Created Equally? Lars Budäus1, Hendrik Isbarn2, Sascha A. Ahyai3, Felix K. H. Chun3, Claudio Jeldres1, Alexander Haese2, Hans Heinzer2, Mario Zacharias3, Roman Heuer3, Thomas Steuber2, Georg Salomon2, Thorsten Schlomm2, Paul Perrotte1, Margit Fisch3, Hartwig Huland2, Markus Graefen2, Pierre I. Karakiewicz1 P17. Initial Experience with Prostate Brachytherapy: Ten-Year Results from a Single Surgeon at a Single Institution 3 Al'a Abdo , Laurent Zini , Umberto Capitanio , Hendrik Isbarn4, Claudio Jeldres1, Shahrokh F. Shariat1, Georg Hutterer1, Giovanni Lughezzani1, P22. Effect of Combined EGFR Inhibition and PPAR Gamma-Agonist in Bladder Cancer Therapy Jose J. Mansure, Konrad Szymanski, Roland Nassim, Joice Rocha, Saad AldoUnited Statesri, Saad AldoUnited Statesri, Simone Chevalier, Wassim Kassouf. McGill University Health Center, Montréal, QC, Canada 19 11:15 a.m. P23. The FGFR3 Mutation Is Related to Favorable pT1 Bladder Cancer Bas W. G. van Rhijn1, Bharati Bapat2, Theo H. van der Kwast1, Liyang Liu3, Neil E. Fleshner1, Madelon N. M. van der Aa4, Rati Vajpeyi5, Chris H. Bangma4, Ellen C. Zwarthoff6, Michael A. S. Jewett1, Alexandre R. Zlotta7 University of Toronto, University Health Network, Toronto, ON, Canada; 2University of Toronto and Mount Sinai Hospital, Toronto, ON, Canada; 3Mount Sinai Hospital, Toronto, ON, Canada, 4Josephine Nefkens Institute, Erasmus MC, Rotterdam, Netherlands; 5University Health Network, Toronto, ON, Canada; 6Josephine Nefkens Institute, Erasmus MC, Rotterdam, Netherlands; 7 University of Toronto, University Health Network and Mount Sinai Hospital, Toronto, ON, Canada Gavin M. Langillle, Binyou Zheng, Dawn L. MacLellan Dalhousie University, Halifax, NS, Canada 11:36 a.m. 1 11:18 a.m. Guimin Chang, Zheng Hu, Jodi K. Maranchie University of Pittsburgh Medical Center, Pittsburgh, PA, United States 11:39 a.m. Carcinogenesis in the Rat Ching Wang1, Katsumi Imaida2, Taro Iguchi3, Gabriel P. Haas1 11:21 a.m. Department of Urology, University of Pittsburgh, Pittsburgh, PA, United States; 2Department of Pharmacology, University of Pittsburgh, Pittsburgh, PA, United States 1 11:42 a.m. P25. Soy Isoflavone G-2535 and Bladder Cancer: Molecular Effects in Tumor Tissue and Urine Edward Messing1, KyungMann Kim2, Jason Gee2, Daniel Saltzstein3, Robert Weiss4, Jorge Yao1, P. Anthony di'SantAgnese1, Howard Bailey2. University of Rochester, Rochester, NY, United States; University of Wisconsin–Madison, Madison, WI, United States; 3Urology San Antonio, San Antonio, TX, United States; 4Yale University School of Medicine, New Haven, CT, United States McGill University, Montréal, QC, Canada; 2Universite de Montréal, Montréal, QC, Canada 1 11:45 a.m. MUHC, Montréal, QC, Canada; 2McGill UniversityMUHC, Montréal, QC, Canada 1 11:48 a.m. P26. Reconstruction of an Autologous Urethral Model by Tissue Engineering Labortoire d'Organogénèse Expérimentale (LOEX), Quebec, QC, Canada P27. Effect of Varicocelectomy on Sperm Chromatin and DNA Integrity Hospital Clinic, Barcelona, Spain; 2Memorial SloanKettering Cancer Center, New York,, NY, United States; 3University of Toronto, University Health Network, Toronto, ON, Canada; 4University of Texas, Southwestern Medical Center, Dallas, TX, United States 1 Raed Azhar, Abdulaziz Baazeem, Maria San Gabriel, Armand Zini McGill University, Montréal, QC, Canada P28. Pilot Study on WST11 Safety and Efficacy for Vascular Targeted Photodynamic Therapy in the Dog Prostate Maurice Anidjar1, Eleonora Scarlata1, Lucie Hamel1, Sabri Moussa1, Konrad Szymanski1, Mostafa Elhilali1, Avigdor Scherz2, Herve Ficheux3, Simone Chevalier1. 20 1McGill University Health Center-Research Institute, Montréal, QC, Canada; 2Weizmann Institute, Rehovot, Israel; 3STEBA, Paris, France 11:33 a.m. P29. Regulation of Apoptosis in Renal Epithelial Cells by Annexin A1 During Mechanical Stress P34. Androgen Receptor (AR) and Bladder Cancer: A Large Bi-Institutional Study on 473 Patients Carmen Mic1, Shahrokh Shariat2, Theodorus Van der Kwast3, Raheela Ashfaq4, Yair Lotan4, Sean Skeldon3, Sally Hanna3, Sultan AlKhateeb3, Juan Morote1, Bas Van Rhijn3, Neil Fleshner3, Michael Jewett3, Alexandre R. Zlotta3 Gabrielle Ouellet, Geneviève Bernard, Stéphane Bolduc 11:30 a.m. P33. Peroxiredoxins: Novel Antioxidant Enzymes of Human Spermatozoa Angela Souza1, Cristian O'Flaherty2 2 11:27 a.m. P32. Early Induction of Erectile Dysfunction by Angiotensin II in the Rat Robert L. Segal1, Frederic Mampouma2, Taben M. Hale2, Serge Carrier1, Denis deBlois2 1 11:24 a.m. P31. Frequency Dependent Pudendal Neuromodulation and Opiate Receptor Involvement in the Pudendal-to-Bladder Reflex in Cats Mang L. Chen1, Bing Shen2, Jicheng Wang1, Hailong Liu1, James R. Roppolo2, William C. de Groat2, Changfeng Tai2 P24. Role of NF-B In Bladder 1SUNY Upstate Medical University, Syracuse, NY, United States; 2Kagawa University Medical School, Kagawa, Japan; 3Osaka City University Medical School, Osaka, Japan P30. Specific NADP(H) Oxidase Inhibition Abrogates HIF Transactivation and the Tumorigenic Phenotype of Renal Cancer Cells 11:51 a.m. Noon Noon – 1:30 p.m. 1:30 – 2:45 p.m. 1:30 p.m. 1:35 p.m. Discussion Adjourn Sneak Peek Luncheon in Exhibit Hall Plenary Session II Welcome and Introduction Testosterone Supplementation and Its Risks Shahrokh Shariat, Dallas Texas, United States Panel: Francesco Montorsi, Gerald Brock, Serge Carrier, Pierre Karakiewicz Moderators: Peter Chan and Pierre Karakiewicz Northeastern Section of the AUA — 2009 Annual Meeting 2 p.m. Prostatitis: A Phoenix Rising from the Ashes Khurshid A. Guru1, Thenkurussi Kesavadas2, Ankur Baheti2, Govindarajan Srimathveeravalli2 J. Curtis Nickel, 1Roswell Park Cancer Institute, Buffalo, NY, United States; 2State University of New York at Buffalo, Buffalo, NY, United States Kingston General Hospital, Kingston, Ontario, Canada 2:45 – 3:15 p.m. 3:15 – 5 p.m. 3:15 – 3:45 p.m. 3:45 – 4 p.m. 4 – 5 p.m. 4 p.m. Panel: Martine Jolivet-Tremblay, Robert M. Moldwin and Serge Carrier Moderators: Bruno Laroche and Jerzy Gajewski Break in Exhibit Hall Concurrent Poster Sessions View Posters Welcome and Introduction Moderated Poster Session III: Robotics, Endoscopy and Laparoscopy Moderator: Hassan Razvi and Barry Kogan P35. A Multi-Centre Randomized Trial Comparing Bipolar vs. Monopolar Transurethral Resection of the Prostate 4:15 p.m. Matthew M. Lux, Jorge Yao, Jean V. Joseph University of Rochester, Rochester, NY, United States 4:18 p.m. University of Rochester, Rochester, NY, United States 4:21 p.m. Schulich School of Medicine and Dentistry, London, ON, Canada Claudio Jeldres1, Hendrik Isbarn2, Umberto Capitanio3, Laurent Zini4, Naeem Bhojani5, Shahrokh F. Shariat5, Vincent Cloutier4, Jean-Baptiste Lattouf5, Alain Duclos5, Martine Jolivet-Tremblay5, Luc Valiquette5, Fred Saad1, Markus Graefen2, Francesco Montorsi3, Paul Perrotte5, Pierre I. Karakiewicz1 University of Montréal Health Center, Montréal, QC, Canada; 2Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany; 3Vita-Salute San Raffaele, Milan, Italy; 4Lille University Hospital, Lille, France; 5University of Montréal, Montréal, QC, Canada 1 4:06 p.m. Roswell Park Cancer Institute, Buffalo, NY, United States 4:24 p.m. University of Montréal, Montréal, QC, Canada 4:27 p.m. Jeffrey J. Tomaszewski, Marc C. Smaldone, Stephen V. Jackman, Timothy D. Averch University of Rochester, Rochester, NY, United States; Rochester General Hospital, Rochester, NY, United States 1 2 4:30 p.m. P38. Validation of Real-Time, Intra- Operative, Surgical Competence (RISC) Assessments Linked to Patient Outcomes McMaster University, Hamilton, ON, Canada University of Toronto, Toronto, ON, Canada P39. Can Human Anatomy be Taught Through the Lenses of a Virtual Reality Simulator? P45. The Value of Transrectal Ultrasound in Predicting Prostate Weights and Outcomes Following Laparoscopic Radical Prostatectomy Jason Kovac, Adeel Sheikh, Ayman Raees, Bobby Shayegan, John P. Whelan, Edward D. Matsumoto Ethan D. Grober, Matthew Roberts, Mohammed Mahdi, Wonnie Shin, Michael AS Jewett 4:12 p.m. P44. Robotic-Assisted Transvesical Prostatectomy for Benign Prostatic Hypertrophy: Description of Technique and Operative and Post-Operative Data of Initial Series of Six Patients Allison L. Cardin1, Eric A. Singer1, Jonah Marshall1, Dragan Golijanin1, John Valvo2, Louis Eichel2, Frederick Tonetti2 Radiologist During Percutaneous Nephrolithotomy 4:09 p.m. P43. Laparoscopic Nephroureterectomy Does Not Undermine Cancer Control Outcomes in Selected Patients with Non-metastatic Upper Tract Urothelial Carcinoma: A Multi-Institutional Analysis of 1249 Cases Al'a Abdo, Claudio Jeldres, Naeem Bhojani, Daniel Liberman, Fred Saad, Francois Benard, Luc Valiquette, Paul Perrotte, Pierre I. Karakiewicz P37. Renal Access by Urologist or University of Pittsburgh School of Medicine, Pittsburgh, PA, United States P42. Simplified Laparoscopic Partial Nephrectomy Using a Single-Layer Closure and No Bolsters for Central Renal Tumors Matthew Hayn, Khurshid Guru, Hyung Kim P36. Development and External Validation of a Highly Accurate Nomogram for the Prediction of Perioperative Mortality After Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia P41. Does Obesity Affect Outcomes in Extraperitoneal Robot-Assisted Prostatectomies? Matthew M. Lux, Tricia D. Greene, Jean V. Joseph Carlos E. Mendez Probst, Linda Nott, Hassan Razvi 4:03 p.m. P40. Does Prostate Size Matter? An Evaluation of Patients Undergoing Robot-Assisted Prostatectomy 4:33 p.m. P46. Robotics in Urology: Comparative International Contemporary Practice Patterns 21 Bertram Yuh1, Rameela Chandrasekhar2, Abid Hussain2, Gregory Wilding2, James Mohler2, Mani Menon3, James Peabody3, Khurshid Guru2 4:03 p.m. University of Buffalo, Buffalo, NY, United States; Roswell Park Cancer Institute, Buffalo, NY, United States; 3Henry Ford Hospital, Detroit, MI, United States 1 Jose Mansure, Roland Nassim, Simone Chevalier, Joice Rocha, Eleonora Scarlata, Wassim Kassouf 2 Current Status of Robot-Assisted Surgery in Urology: A Multi-National Survey of 297 Urologic Surgeons McGill University Health Center, Montréal, QC, Canada 4:06 p.m. Khurshid A. Guru1, Rameela Chandrasekhar2, Abid Hussain1, Pamela Piacente1, Marlene Bienko1, Mark Glasgow2, Willie Underwood1, Gregory Wilding2, James L. Mohler1, Mani Menon3, James O. Peabody,3 1Roswell Park Cancer Institute, Buffalo, NY, United States; 2State University of New York at Buffalo, Buffalo, NY, United States; 3Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI, United States 4:36 p.m. P47. Comparison of Extraperitoneal and University of Montréal, Montréal, QC, Canada; Vita Salute University San Raffaele, Milan, Italy 1 2 4:09 p.m. P48. Early Post-Operative Renal Tants University, Tanta, Egypt 4:12 p.m. Scintigraphy as a Predictor of LongTerm Outcomes After Laparoscopic Pyeloplasties 1Centre Hospitalier Universitaire de Quebec, Québec, QC, Canada; 2Université Laval, Québec, QC, Canada P49. From Laparoscopic to RoboticAssisted Pyeloplasty: Our Extended Experience Bishoy A. Gayed, Bruce L. Jacobs, Tina K. Schuster, Timothy D. Averch University of Montréal, Montréal, QC, Canada; 2VitaSalute San Raffaele, Milan, Italy; 3Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany 1 4:15 p.m. University of Pittsburgh, Pittsburgh, PA, United States 4:45 p.m. 5 p.m. 4 – 5 p.m. 4 p.m. 22 P55. Stage Distribution at Radical Cystectomy During the Last Two Decades Al'a Abdo, Claudio Jeldres, Daniel Liberman, Naeem Bhojani, Fred Saad, Luc Valiquette, Paul Perrotte, Pierre I. Karakiewicz Discussion Adjourn Moderated Poster Session IV: Bladder Cancer Moderators: Paul Perrotte and Alexandre R. Zlotta P50. A Comparative Survival Analyses of 4:18 p.m. Nonbilharzial Squamous Cell Carcinoma vs. Transitional Cell Carcinoma After Radical Cystectomy 4:21 p.m. Nawar Hanna1, Claudio Jeldres1, Sara Baillargeon-Gagne1, Hendrik Isbarn1, Umberto Capitanio1, Shahrokh F. Shariat1, Giovanni Lughezzani1, Maxine Sun1, Fred Saad1, Paul Perrotte1, Francesco Montorsi2, Markus Graefen3, Pierre I. Karakiewicz1 P54. A Population-Based Assessment of Perioperative Mortality After Cystectomy for Bladder Cancer Claudio Jeldres1, Hendrik Isbarn1, Laurent Zini1, Paul Perrotte1, Sara Baillargeon-Gagne1, Umberto Capitanio1, Shahrokh F. Shariat1, Philippe Arjane1, Fred Saad1, Michael McCormack1, Luc Valiquette1, Francois Peloquin1, Alain Duclos1, Francesco Montorsi2, Markus Graefen3, Pierre I. Karakiewicz1 Michel Hugues Lebel1, Frederic Pouliot1, David Méthot-Langevin2, Jean-François Audet1, Thierry Dujardin1 4:42 p.m. P53. Combined Modality Treatment with Bladder Preservation for Muscle Invasive Bladder Cancer Magdy A. Sabaa Sr. Matthew M. Lux, Erdal Erturk, Jean V. Joseph 4:39 p.m. P52. A Comparative Survival Analysis of Adenocarcinoma vs. Transitional Cell Carcinoma After Radical Cystectomy Radoslav Krouchev1, Giovanni Lughezzani1, Claudio Jeldres1, Sara Baillargeon-Gagne1, Hendrik Isbarn1, Daniel Liberman1, Paul Perrotte1, Fred Saad1, Luc Valiquette1, Francesco Montorsi2, Pierre I. Karakiewicz1 Transperitoneal Robot-Assisted Radical Prostatectomy in the Obese Patient University of Rochester, Rochester, NY, United States P51. mTOR Inhibitor RAD001 (everolimus) Has Significant Antitumor Activity in Bladder Cancer University of Montréal, Montréal, QC, Canada P56. The Incidence of Prostate Cancer and Urothelial Cancer in the Prostate in Cystoprostatectomy Specimens Sri Sivalingam, Darrel Drachenberg University of Manitoba, Winnipeg, MB, Canada P57. Management and Outcome of Patients Who Had Unresectable Disease Upon Exploratory Laparotomy for Bladder Cancer Faysal A. Yafi, Marie Duclos, José A. Correa, Simon Tanguay, Armen G. Aprikian, Fabio Cury, Luis Souhami, Raghu Rajan, Wassim Kassouf McGill University, Montréal, QC, Canada University of Montréal, Montréal, QC, Canada; 2Vita-Salute San Raffaele, Milan, Italy; 3Martiniclinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany 1 Northeastern Section of the AUA — 2009 Annual Meeting 4:24 p.m. P58. Impact of Sub-Stage and Pathology Faysal A. Yafi1, Armen G. Aprikian1, Yves Fradet2, Joe Chin3, Jonathan Izawa3, Ricardo Rendon4, Eric Estey5, Adriane Fairey5, Ilias Cagiannos6, Louis Lacombe2, Jean-Baptiste Lattouf7, David Bell4, Darrel Drachenberg8, Wassim Kassouf1 Review on the Clinical Outcome of pT1 Bladder Cancer Bas W. G. van Rhijn1, Theo H. van der Kwast1, David Kakiashvili1, Neil E. Fleshner1, Sultan Alkhateeb1, Madelon N. M. van der Aa2, Rati Vajpeyi3, Chris H. Bangma2, Michael A. S. Jewett1, Alexandre R. Zlotta1 1McGill University, Montréal, QC, Canada, 2Laval University, Quebec, QC, Canada; 3University of Western Ontario, London, ON, Canada; 4Dalhousie University, Halifax, NS, Canada; 5University of Alberta, Edmonton, AB, Canada; 6University of Ottawa, Ottawa, ON, Canada; 7University of Montréal, Montréal, QC, Canada; 8University of Manitoba, Winnipeg, MB, Canada 1University of Toronto, University Health Network, Toronto, ON, Canada; 2Josephine Nefkens Institute, Erasmus MC, Rotterdam, Netherlands; 3University Health Network, Toronto, ON, Canada 4:27 p.m. P59. Long-term Follow-Up for Primary 4:42 p.m. T1 High-Grade Bladder Cancer—Does BCG Really Prevent Progression? David Kakiashvili1, Bas W. G. van Rhijn1, Michael A. S. Jewett1, Neil E. Fleshner1, Julian Azzuero1, Alex Kostynskyy2, Chris H. Bangma3, Theodorus H. Van Der Kwast1, Alexandre R. Zlotta1 Edward Messing1, Yves Fradet2, Alvaro Morales3, Lance Mynderse4, Mark Soloway5, Unyime Nseyo6, Seth Lerner7, H. Barton Grossman8 1University of Toronto, University Health Network, Toronto, ON, Canada; 2University Health Network, Toronto, ON, Canada; 3Josephine Nefkens Institute, Erasmus MC, Rotterdam, Netherlands 4:30 p.m. University of Rochester, Rochester, NY, United States; U'Laval University, Quebec, QC, Canada; 3Kingston General Hospital, Kingston, ON, Canada; 4Mayo Clinic, Rochester, MN, United States; 5University of Miami, Miami, FL, United States; 6University of Florida, Gainesville, FL, United States; 7Baylor College of Medicine, Houston, TX, United States; 8MD Anderson, Houston, TX, United States 1 2 P60. What Is the Long-Term Prognostic Value of Pro-Apoptotic, Anti-Apoptotic, Proliferation and Invasiveness Molecular Markers in Patients Treated with BCG for High Risk Non-Muscle Invasive Bladder Cancer? S. Alkhateeb1, MG Neill1, B. Van Rhijn1, D. Kakiashvili1, N. Fleshner1, M. Jewett1, S. Bar-Moshe2, M. Petein2, C. Schulman2, T. Roumeguere2, S. Rorive2, Alexandre R. Zlotta1 University of Toronto, University Health Network, Toronto, ON, Canada; 2Erasme Hospital and University Clinics of Brussels, Brussels, Belgium 4:45 p.m. McGill University, Montréal, QC, Canada 4:48 p.m. P61. Does Screening for Bladder Cancer Produce a Stage Migration Towards Non-Muscle Invasive Cancers? Alexandre R. Zlotta1, T. Roumeguere2, S. Alkhateeb1, S. Rorive2, A. Lemy2, I. Salmon2, M. Wissing2, D. Abramowicz2, C. Schulman2, N. Fleshner1, M. Jewett1, J. Nortier2 University of Toronto, University Health Network, Toronto, ON, Canada; 2Erasme Hospital and University Clinics of Brussels, Brussels, Belgium P62. Cost Analysis of a Single Instillation of Mitomycin C after Transurethral Resection of Bladder Tumor in the Quebec Health Care System P66. Combining mTOR Inhibitor (RAD001) with Ionizing Radiation: A Novel Strategy for the Treatment of Bladder Cancer Roland Nassim1, Jose Joao Mansure2, Simone Chevalier1, Fabio Cury2, Wamied Abdul Rahman2, Ismail Al-Dahlawi2, Wassim Kassouf1 McGill University, Montréal, QC, Canada; 2McGill University Health Center, Montréal, QC, Canada 1 1 4:36 p.m. P65. Survey on the Work-Up and Screening of Hematuria Among General Practitioners in Quebec Faysal A. Yafi, Armen G. Aprikian, Simon Tanguay, Wassim Kassouf 1 4:33 p.m. P64. Florescence Cystoscopy with Hexaminolevulinate (HAL) Improves Detection Rate of Ta and T1 Bladder Cancer and Reduces Recurrence Following TURBT at Nine Months 4:51 p.m. 5 p.m. 5:30 – 6:30 p.m. 7 – 9 p.m. Discussion Adjourn Exhibit Hall Grand Opening/Welcome Reception Networking Reception Robert L. Segal, Andrew Feifer, Xuanqian Xie, James M. Brophy, Wassim Kassouf McGill University, Montréal, QC, Canada 4:39 p.m. P63. Surveillance Guidelines Based on Recurrence Patterns Following Radical Cystectomy for Bladder Cancer: The Canadian Bladder Cancer Network Experience 23 FRIDAY, OCTOBER 9, 2009 6 – 7:30 a.m. 11:03 a.m. New Treatments for Erectile Dysfunction Following Radical Prostatectomy: Focus on Soft Glans Challenges J. Letendre, D. Barrieras, A.M. Houle, K. Keu, R. Lambert, S. Turpin, J. Franc-Guimond Andrew R. McCullough New York University School of Medicine, New York, NY, United States Sponsored by VIVUS, Inc. 6:30 – 8 a.m. 7:30 – 7:45 a.m. 7:45 – 8:45 a.m. 7:45 a.m. 8:15 a.m. 8:45 – 9:45 a.m. 8:45 a.m. CHU Sainte-Justine, Montréal, QC, Canada 11:06 a.m. Laval University, Québec, QC, Canada 11:09 a.m. Plenary Session III: Section Stars Moderator: Anne-Marie Houle Prize Essay Winners: P27, P31 and P81 Past NS-AUA Young Investigator Grant Recipients Anthony J. Bella (2007 Recipient) University of Ottawa Ottawa, ON Canada Molecular Mechanisms of Cavernous Nerve Regeneration Following Prostate Cancer Treatment in men with Metabolic Syndrome Update Jehonathan Pinthus (2008 Recipient) Juravinski Cancer Center-Hamilton Health Sciences Hamilton, OH Canada Obesity and RCC- the Adiponectin Axis as a Link Plenary Session IV Montréal Children’s Hospital, Montréal, QC, Canada 11:12 a.m. Université Laval, Québec, QC, Canada 11:15 a.m. Hypospadias Repair: A Series of 161 Patients 24 Marie-Pier Deschênes Rompré, Katherine Moore, Stéphane Bolduc Université Laval, Québec, QC, Canada P72. Solifenacin for Overactive Bladder in Children: A Prospective Open-Label Study Stéphane Bolduc, Katherine Moore CHUL, Québec, QC, Canada 11:18 a.m. P73. Percutaneous Management of Urolithiasis in Children and Adolescents with Spinal Cord Lesions Bishoy A. Gayed, Marc C. Smaldone, Michael C. Ost Cleveland Clinic, Cleveland, Ohio, United States Panelists: Edward Messing, John M. Fitzpatrick, and Alexandre R. Zlotta Moderator: Pierre Karakiewicz 9:45 – 10:15 a.m. Break in Exhibit Hall 10:15 a.m. – Noon Concurrent Poster Sessions 10:15 – 10:45 a.m. View Posters 10:45 – 11 a.m. Welcome and Introduction 11 a.m. – Noon Moderated Poster Session V: Pediatric Urology Moderators: Philip G. Ransley and Anne-Marie Houle 11 a.m. P67. TIP Urethroplasty in Primary P71. Study on Hydrophilic-Coated Catheter Appreciation in a Pediatric Population Andréanne Boucher, Jonathan Cloutier, Sylvie Lebel, Micheline Hamel, Pascale Lamontagne, Stéphane Bolduc Eric A. Klein Universitá Vita Salute, Milan, Italy P70. Dye-Assisted Lymphatic-Sparing Laparoscopic Varicocelectomy in Children: Initial Experience Waleed Eassa, Mohammed El-Sherbiny, Roman Jednak, John-Paul Capolicchio PSA Screening Francesco Montorsi P69. Study Comparing the Applicability of Dorsal Lumbotomy in Older Children Jonathan Cloutier, Nadim Haidar, Marie-Pier Rompré, Maryse Grimard, Stephane Bolduc 5K Run/Walk Best-of-Poster Sessions Presented by moderators of previous day’s poster sessions P68. Assessing Ureteropelvic Junction Obstruction (UPJO) Using Original Renographic Criteria for a Decade Proves to be Reliable Industry-Sponsored Breakfast Symposium University of Pittsburgh, Pittsburgh, PA, United States 11:21 a.m. P74. Ethical Considerations in the Management of Cryptorchidism in the Profoundly Disabled Eric A. Singer, Danielle R. Wendel, Nadia A. Awad, Richard A. Demme, Jane Greenlaw, William C. Hulbert, Jr., Robert A. Mevorach, Ronald Rabinowitz University of Rochester Medical Center, Rochester, NY, United States 11:24 a.m. P75. High Cost, Minimal Benefit: A Cost-Benefit Analysis of Ultrasound in the Management of Adolescent Varicocele Adam Walker, Barry Kogan Albany Medical Center, Albany, NY, United States 11:27 a.m. P76. Can We Avoid Removing the Adrenal Gland at the Time of Radical Nephrectomy in Children with Wilms Tumor? Northeastern Section of the AUA — 2009 Annual Meeting Armando J. Lorenzo1, Katherine Moore1, Bruno Leslie1, Stephane Bolduc2 Hospital for Sick Children, Toronto, ON, Canada; Centre Hospitalier Universitaire de Québec, Quebec, QC, Canada 11a.m. – Noon 1 2 11:30 a.m. 11 a.m. Migration in Surgically-Treated Patients with Upper Urinary Tract Transitional Cell Carcinoma P77. Are There Risk Factors for Perinatal Torsion? Lei Chu, Michael C. Ost, Steven G. Docimo, Mark F. Bellinger, Francis X. Schneck P78. Evaluation of Hydronephrosis in Pediatric Kidney Transplants and its Clinical Relevance Giovanni Lughezzani1, Claudio Jeldres1, Hendrik Isbarn1, Maxine Sun1, Shahrokh F. Shariat1, Daniel Liberman1, Hugues Widmer1, Philippe Arjane1, Daniel Pharand1, Markus Graefen2, Paul Perrotte1, Francesco Montorsi3, Pierre I. Karakiewicz1 Lei Chu, Bruce L. Jacobs, Michael C. Ost, Mark F. Bellinger, Steven G. Docimo, Francis X. Schneck University of Montréal, Montréal, QC, Canada; Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany; 3Vita-Salute University, Milan, Italy University of Pittsburgh, Pittsburgh, PA, United States 11:33 a.m. University of Pittsburgh, Pittsburgh, PA, United States 11:36 a.m. 1 2 11:03 a.m. P79. Retroperitoneoscopic Nephrectomy in Children on Peritoneal Dialysis: The Gold Standard Montréal Children’s Hospital, Montréal, QC, Canada P80. Long-Term Functional Outcome After Primary Repair of Classic Bladder Exstrophy University of Montréal, Montréal, QC, Canada; Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany; 3Vita-Salute University, Milan, Italy 1 Waleed Eassa, Roman Jednak, John Paul Capolicchio, Mohamed T. El Sherbiny Montréal Children’s Hospital, Montréal, QC, Canada 11:42 a.m. P81. In Vitro Reconstruction of an 2 11:06 a.m. Autologous, Watertight and Resistant Vesical Equivalent Stéphane Bolduc P82. Serosal Lined Extramural Tunnel Principle in the Creation of a Catheterizable Channel in Bladder Augmentation: The Video Mohamed T. El Sherbiny, Waleed Eassa University of Montréal, Montréal, QC, Canada; Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany; 3Vita-Salute San Raffaele, Milan, Italy 1 2 11:09 a.m. Montréal Children’s Hospital, Montréal, QC, Canada 11:48 a.m. P83. Dextranomer/Hyaluronic Acid Copolymer (Deflux) Injections in a Teaching Center: The Real Picture CHU Sainte-Justine, Montréal, QC, Canada P84. The Anterior Approach to Retroperitoneoscopic Adrenalectomy in Children Waleed Eassa, Mohammed El-Sherbiny, Roman Jednak, John-Paul Capolicchio Montréal Children’s Hospital, Montréal, QC, Canada 11:54 a.m. Noon Discussion Adjourn P88. The Impact of Tumor Stage and Nodal Metastases on Cancer Specific Mortality in Patients with Upper Urinary Tract Transitional Cell Carcinoma: Results from a Population-Based Study Giovanni Lughezzani1, Claudio Jeldres1, Hendrik Isbarn1, Maxine Sun1, Shahrokh F. Shariat1, Daniel Pharand1, Hugues Widmer1, Philippe Arjane1, Markus Graefen2, Paul Perrotte1, Francesco Montorsi3, Pierre I. Karakiewicz1 Julie Franc-Guimond, Julien Letendre, Diego Barrieras, Anne-Marie Houle 11:51 a.m. P87. Segmental Ureterectomy Can Safely Be Performed in Patients with Ureteral Upper Tract-Transitional Cell Carcinoma Daniel Liberman1, Claudio Jeldres1, Giovanni Lughezzani1, Hendrik Isbarn1, Maxine Sun1, Shahrokh F. Shariat1, Daniel Pharand1, Philippe Arjane1, Margit Fisch2, Markus Graefen2, Francesco Montorsi3, Paul Perrotte1, Pierre I. Karakiewicz1 Laval University, Quebec, QC, Canada Sara Bouhout, Émilie Perron, Robert Gauvin, Geneviève Bernard and Stéphane Bolduc Laval University, Quevec, QC, Canada 11:45 a.m. P86. An Assessment of the Prognostic Significance of Tumor Grade in Patients with Upper Urinary Tract Transitional Cell Carcinoma: A Population-Based Study Giovanni Lughezzani1, Claudio Jeldres1, Hendrik Isbarn1, Maxine Sun1, Shahrokh F. Shariat1, Daniel Pharand1, Hugues Widmer1, Philippe Arjane1, Markus Graefen2, Francesco Montorsisale3, Paul Perrotte1, Pierre I. Karakiewicz1 Konrad M. Szymanski, Martin Bitzan, John-Paul Capolicchio 11:39 a.m. Moderated Poster Session VI: Oncology Moderator: Pierre Karakiewicz P85. Temporal Stage and Grade University of Montréal, Montréal, QC, Canada; Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany; 3Vita-Salute University, Milan, Italy 1 2 11:12 a.m. P89. Patients with Renal Pelvis Upper Tract Transitional Cell Carcinoma Have Significantly Worse Cancer-Specific Survival than Patients with Ureteral Primaries 25 Daniel Liberman1, Claudio Jeldres1, Al'a Abdo1, Fred Saad1, Francois Benard1, Luc Valiquette1, Francesco Montorsi2, Paul Perrotte1, Pierre I. Karakiewicz1 Claudio Jeldres1, Maxine Sun1, Hendrik Isbarn1, Giovanni Lughezzani1, Shahrokh F. Shariat1, Daniel Pharand1, Hugues Widmer1, Philippe Arjane1, Francesco Montorsi2, Paul Perrotte1, Pierre I. Karakiewicz1 University of Montréal, Montréal, QC, Canada; Vita-Salute San Raffaele, Milan, Italy 1 11:15 a.m. 2 1 P90. A Population-Based Assessment 2 of Perioperative Mortality After Nephroureterectomy for Upper-Tract Transitional Cell Carcinoma Claudio Jeldres1, Maxine Sun1, Hendrik Isbarn1, Giovanni Lughezzani1, Shahrokh F. Shariat1, Daniel Liberman1, Hugues Widmer1, Daniel Pharand1, Philippe Arjane1, Markus Graefen2, Francesco Montorsi3, Paul Perrotte1, Pierre I. Karakiewicz1 University of Montréal, Montréal, QC, Canada; Vita-Salute San Raffaele, Milan, Italy 11:30 a.m. Geneviève Nadeau, François Harel, Pierre Douville, Yves Fradet, Louis Lacombe Laval University, Quebec, QC, Canada 11:33 a.m. University of Montréal, Montréal, QC, Canada; Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany; 3Vita-Salute San Raffaele, Milan, Italy 1 2 11:18 a.m. Valerie Deslauriers1, Giovanni Lughezzani1, Hendrik Isbarn1, Claudio Jeldres1, Maxine Sun1, Shahrokh F. Shariat1, Daniel Pharand1, Hugues Widmer1, Philippe Arjane1, Markus Graefen2, Paul Perrotte1, Francesco Montorsi3, Pierre I. Karakiewicz1 University of Pittsburgh School of Medicine, Pittsburgh, PA, United States 11:36 a.m. University of Pittsburgh School of Medicine, Pittsburgh, PA, United States 11:39 a.m. University of Montréal, Montréal, QC, Canada; Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany; 3Vita-Salute University, Milan, Italy 2 P92. Significance of Positive Bladder Cuff in Nephroureterectomy Specimen in Patients with Upper Urinary Tract Urethelial Tumors Yasser Osman, Mohamed El Awady, Mahmoud Kenawy, Mohamed Gaballa, El-Housseiny Ibrahiem 1The Urological Institute of Northeastern New York, Albany, NY, United States; 2GTx, Inc, Memphis, TN, United States 11:42 a.m. Post-Nephroureterctomy for Upper Urinary Tract-Urothelial Carcinoma, Analysis of Risk Factors McGill University, Montréal, QC, Canada 11:45 a.m. 26 P94. Development and External Validation of a Highly Accurate Nomogram for the Prediction of Cancer-Specific Mortality After Nephroureterectomy for Upper Tract Transitional Cell Carcinoma P100. Comparison of the Costs of Active Surveillance vs. Radical Prostatectomy Anthony T. Corcoran, Ronald M. Benoit University of Pittsburgh Medical Center, Pittsburgh, PA, United States Mansoura Urology and Nephrology Center, Mansoura, Egypt 11:27 a.m. P99. Retroperitoneal Lymph Node Dissection of Post-Chemotherapy Residual Masses for Metastatic Germ Cell Testicular Cancer Murilo A. Luz, Simon Tanguay, Wassim Kassouf, Ahmed F. Kotb, Saad Aldousari, Armen G. Aprikian P93. Intravesical Recurrence Yasser Osman, Mohamed El Awady, Mahmoud Kenawy, Mohamed Gaballa, El-Housseiny Ibrahiem P98. Toremifene 80 Mg Phase 3 Trial in Men on ADT Demonstrates Improvement in Gynecomastia Compared to Placebo. Hugh Fisher1, Ronald Kaufman1, Ronald A. Morton2. Mansoura Urology and Nephrology Center, Mansoura, Egypt 11:24 a.m. P97. Treatment and Outcomes of Bladder Cancer Following Solid Organ Transplantation Jeffrey J. Tomaszewski, Jeff Larson, Marc C. Smaldone, Stephen V. Jackman 1 11:21 a.m. P96. Cesium-131 Versus Iodine-125 Implants for Prostate Cancer: Evaluation of Early PSA Response Jeffrey J. Tomaszewski, Marc C. Smaldone, Ronald M. Benoit P91. Gender-Related Differences in Patients with Upper Urinary Tract Transitional Cell Carcinoma: Results from the Surveillance, Epidemiology and End Results Database P95. Prognostic Value of Insulin-Like Growth Factor-I and Binding Proteins 2 and 3 in Patients Treated with Radical Prostatectomy 11:48 a.m. P101. Phase III Trial in Men on ADT Demonstrates a Reduction in Hot Flashes in Men on Toremifene 80 mg Compared to Placebo Jeff Gingrich1, Philip Aliotta2, Ronald A. Morton3 Pittsburgh VA Health Care Center, Pittsburgh, PA, 1 Northeastern Section of the AUA — 2009 Annual Meeting United States; 2Center for Urologic Reseach of WNY, LLC, Williamsville, NY, United States; 3GTx, Inc, Memphis, TN, United States 11:51 a.m. Noon 1:15 – 3 p.m. 1:15 p.m. 1:20 p.m. Discussion Adjourn Plenary Session V 1Watson Laboratories, Inc, Salt Lake City, UT, United States; 2Urology Associates/Urology Medical Research, Kitchner, ON, Canada 4:15 p.m. Welcome and Introduction Prostate Cancer Chemo Prevention P107. Utility of an Ambulatory Pessary Trial to Unmask Occult Stress Urinary Incontinence Bilal Chughtai, Elise J. B. De Albany Medical Center, Albany, NY, United States Eric A. Klein, Cleveland Clinic, Cleveland, Ohio, United States 4:18 p.m. Panelists: John Fitzpatrick and Alexandre Zlotta Moderator: Shahrokh Shariat 2:15 p.m. AUA Course of Choice: Interstitial Cystitis/Painful Bladder Syndrome and Related Conditions: Practical Management Strategies Andrew R. McCullough, Brianne Goodwin, Herbert Lepor Moderator: Luc Valiquette Robert Moldwin New York University School of Medicine, New York, NY, United States Smith Institute of Urology, New Hyde Park, New York 3:30 – 5 p.m. 3:30 – 3:45 p.m. 3:45 – 4 p.m. 4 – 5 p.m. 4 p.m. Concurrent Poster Sessions View Posters Welcome and Introduction Moderated Poster Session VII: General Urology Moderators: Peter Chan and J. Curtis Nickel P102. Research in Urology: A National 4:21 p.m. University of Rochester, Rochester, NY, United States 4:24 p.m. Jason Izard, D. Robert Siemens P103. Suprasacral Spinal Cord Injury Laval, Quebec, QC, Canada 4:27 p.m. John M. Rutkowski, Kevan Pranikoff, Jan Capuana Queen's University, Kingston, ON, Canada; 2Cleveland Clinic, Cleveland, OH, United States 1 P104. Surgical Treatment of Bladder Outlet Obstruction Improves Outcome in Male Interstitial Cystitis 4:30 p.m. Roger E. Vega UPMC St. Margaret, Pittsburgh, PA, United States 4:09 p.m. Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke, QC, Canada 4:33 p.m. Emmanuel O. Abara1, Sylvia Naughton2, Oge Abara3, Rob Williams4 York Central Hospital, Richmond Hill, ON, Canada; Ontario Telemedicine Network, Barrie, ON, Canada; 3University of Toronto, Toronto, ON, Canada; 4Ontario Telemedicine Network, Timmins, ON, Canada 1 2 4:12 p.m. Laboratoire d’Organogénèse expérimentale/LOEX, CHA, Hôpital du St-Sacrement, Québec, QC, Canada ® 1 2 Keshava N. Kumar , Blair R. Egerdie , Weining Volinn1, Lawrence Hill1, Gary Hoel P113. An Autologous Tissue-Engineered Endothelialized Graft: A Possible Option in the Surgical Correction of Peyronie’s Disease Annie Imbeault, Geneviève Bernard, Gabrielle Ouellet, Sara Bouhout, Stéphane Bolduc P106. An Open-Label, Multi-Center Pharmacokinetic Study of Uracyst 400 mg Following a Single Bladder Instillation in Subjects with Interstitial Cystitis/Painful Bladder Syndrome P112. Mid-Term Results of Pelvic Organ Prolapse Repair Using a Transvaginal Mesh: The Sherbrooke Experience Louis-Olivier Gagnon, Le-Mai Tu P105. Office-Based Urotelehealth— Bringing Urology Health Care Near to Home: A Work in Progress P111. Clinical Phenotyping of Urologic Chronic Pelvic Pain Syndromes (UCPPS): Validation of the “Snowflake Hypothesis” J. Curtis Nickel1, Daniel Shoskes2 University at Buffalo, Buffalo, NY, United States 4:06 p.m. P110. A Comparison Between Composix™-Based Slings, Tension Free Vaginal Tapes Tvt™ and Transobturator Tapes Tvt-o™ at a Median Follow-Up of 24 months Nadim H. Haidar, Katherine Moore, Rachel Sweenor, Mireille Grégoire Kingston General Hospital, Kingston, ON, Canada Patients Managed by Reflex Voiding: Characterization of our Cohort P109. The Impact of Clomiphene Citrate on Severe Idiopathic Oligospermia Jennifer Gordetsky, Jeanne O'Brien Survey on Attitudes and Experience of Research in Urology Residency 4:03 p.m. P108. The Longitudinal Effects on Penile Oxygen Saturation from a Prospective Randomized Study of the Nightly Use of Intraurethral Alprostadil vs. Sildenafil Following Nerve-Sparing Radical Prostatectomy (NSRP) 4:36 p.m. P114. Chondroitin Sulfate Is a Promising Therapy for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS) J. Curtis Nickel1, Blair Egerdie2, Anthony Skehan3, Karen Irvine-Bird1, Joe Downey1 Queen's University, Kingston, ON, Canada; 2Urology 1 27 Associates/Urology Medical Research, Kitchener, ON, Canada; 3Urology, Thunder Bay, ON, Canada 4:39 p.m. 4:06 p.m. P115. MRI-Guided Transurethral Ultrasound Therapy with Real Time Thermal Mapping: Initial Studies Brian Kim1, Luke Lavallee1, Dean Fergusson2, Ilias Cagiannos1 Laurence Klotz, Kashif Siddiqui, Rajif Chopra, Michael Bronskill. University of Ottawa, Ottawa, ON, Canada; 2Ottawa Health Research Institute, Ottawa, ON, Canada 1 Sunnybrook HSC, Toronto, ON, Canada. 4:42 p.m. P116. Recovery of Erectile Function 4:09 p.m. Following Nerve-Sparing Radical Prostatectomy After Penile Rehabilitation with Nightly Intraurethral Alprostadil vs. Sildenafil Citrate New York University School of Medicine, New York, NY, United States; 2University of Texas–MD Anderson Cancer Center and University of Texas Medical School, Houston, TX, United States; 3Texas A & M Health Science Center College of Medicine, Temple, TX, United States; 4Tulane University, New Orleans, LA, United States; 5George Washington University, Washington DC, United States 4:45 p.m. P117. Provider Recommendation and McGill University Health Centre (MUHC), Montréal General Hospital (MGH), Montréal, QC, Canada 4:12 p.m. Roswell Park Cancer Institute, Buffalo, NY, United States 4:15 p.m. Giovanni Lughezzani1, Claudio Jeldres1, Hendrik Isbarn1, Paul Perrotte1, Shahrokh F. Shariat1, Maxine Sun1, Hugues Widmer1, Philippe Arjane1, Francois Peloquin1, Saniel Pharand1, Jean-Jaques Patard2, Markus Graefen3, Francesco Montorsi4, Pierre I. Karakiewicz1 Roswell Park Cancer Institute, Buffalo, NY, United States; 2University of Buffalo, Buffalo, NY, United States; 3University of Michigan, Ann Arbor, MI, United States; 4Vanderbilt University School of Medicine, Nashville, TN, United States 1 P118. Optimization of the Nanolantern™ Assay for Rapid Detection of Common Urinary Tract Pathogens University of Rochester, Rochester, NY, United States 4:51 p.m. 5 p.m. 4 – 5 p.m. 4 p.m. Discussion Adjourn Moderated Poster Session VIII: Kidney Cancer Moderators: John M. Fitzpatrick and Wassim Kassouf P119. Fast Track Open Partial Nephrectomy: A Feasibility Study Bilal Chughtai1, Stuart Rosenberg2, Daniel Finn3, Michael Perrotti3 Albany Medical Center, Albany, NY, United States; 2St Peters Hospital, Albany, NY, United States; 3St Peter's Hospital, Albany, NY, United States 1 4:03 p.m. 28 P120. Role of Biopsy in the Management of Small Renal Masses Bilal Chughtai, Ronald P. Kaufman Jr., Hugh A. G. Fisher, Gary Sisken, Badar Mian Albany Medical Center, Albany, NY, United States P124. Tumor Size is a Determinant of the Rate of Synchronous Metastases in Patients with T1 Stage Renal Cell Carcinoma Willie Underwood, III1, Heather Orom2, Brady West3, Jay Fowkes4 Jennifer G. Rothschild, Christopher M. Strohsahl, Ganesh S. Palapattu, Benjamin L. Miller P123. Preliminary Report of a Pilot Study of Neoadjuvant Sunitinib for Clinical M0 Renal Cell Carcinoma Nicholas Hellenthal, Joel Gajewski, Marcus Sikorski, Hyung Kim Treatment Choice 4:48 p.m. P122. Factors Predicting Renal Impairment on Long-Term Follow-Up, Following Partial Nephrectomy: Mcgill 10 Years Experience Ahmed F. Kotb, Tamer H. Abou Youssif, Murilo A. Luz, Armen Aprikian, Wassim Kassouf, Fadi Brimo, Simon Tanguay Andrew R. McCullough1, Herbert Lepor1, Run Wang2, Kristopher R. Wagner3, Wayne J. G. Hellstrom4, Jason D. Engel5 1 P121. The Impact on Renal Function After Partial vs. Radical Nephrectomy for Renal Cell Carcinoma: A Systematic Review University of Montréal, Montréal, QC, Canada; Rennes University Hospital, Rennes, France; 3Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany; 4Vita-Salute University, Milan, Italy 1 2 4:18 p.m. P125. Conditional Survival Predictions After Nephrectomy for Renal Cell Carcinoma Claudio Jeldres1, Nazareno Suardi1, Umberto Capitanio1, Hendrik Isbarn1, Paul Perrotte1, Vincenzo Ficarra2, Richard Zigeuner3, Jacques Tostain4, Arnaud Mejean5, Luca Cindolo6, Allan J. Pantuck7, Arie S. Belldegrun7, Laurent Zini8, Alexandre de la Taille9, Denis Chautard10, Jean-Luc Descotes11, Shahrokh F. Shariat1, Antoine Valeri12, Peter F. A. Mulders13, Herve Lang14, Eric Lechevallier15, Jean-Jacques Patard16, Pierre I. Karakiewicz1 1 University of Montréal, Montréal, QC, Canada; 2University of Padua, Padua, Italy; 3Medical University of Graz, Graz, Austria; 4University Hospital of Saint-Etienne, Saint-Etienne, France; 5Necker Medical School, Paris, France; 6G. Rummo Hospital, Benevento, Italy; 7 David Geffen School of Medicine, Los Angeles, CA, United States; 8University of Lille, Lille, France; 9Henri Mondor University Hospital, Creteil, France; 10University of Angers, Angers, France; 11Medical University of Northeastern Section of the AUA — 2009 Annual Meeting Grenoble, Grenoble, France; 12Brest University Medical School, Brest, France; 13Radboud University, Nijmegen, Netherlands; 14University of Toulouse, Toulouse, France; 15Marseille University, Marseille, France; 16 Rennes University Hospital, Rennes, France 4:21 p.m. P126. Prognostic Significance of 1University of Montréal, Montréal, QC, Canada; 2Lille University Hospital, Lille, France; 3Vita-Salute San raffaele, Milan, Italy; 4Vita-Salute San Raffaele, Milan, Italy; 5Vita Salute San Raffaele, Milan, Italy; 6Vita-Salute San Raffaele, Montréal, Italy 4:36 p.m. Nephron-Sparing Surgery has the Same Cancer Control than Radical Nephrectomy: A Population-Based Assessment Giovanni Lughezzani1, Umberto Capitanio2, Claudio Jeldres1, Hendrik Isbarn1, Shahrokh F. Shariat1, Philippe Arjane1, Hugues Widmer1, Paul Perrotte1, Francesco Montorsi2, Pierre I. Karakiewicz1 Salima Ismail1, Claudio Jeldres1, Maxime Crepel1, Hendrik Isbarn1, Giovanni Lughezzani1, Maxine Sun1, Daniel Liberman1, Shahrokh F. Shariat1, Daniel Pharand1, Phillippe Arjane1, Francesco Montorsi2, Paul Perrotte1, Pierre I. Karakiewicz1 University of Montréal, Montréal, QC, Canada; Vita-Salute University, Milan, Italy 1 2 4:24 p.m. University of Montréal, Montréal, QC, Canada; Vita-Salute San Raffaele, Milan, Italy 1 P127. Pushing the Limits of Partial Nephrectomy: Time to Pause? 2 4:39 p.m. Claudio Jeldres1, Maxime Crepel1, Umberto Capitanio1, Paul Perrotte1, Hendrik Isbarn1, Giovanni Lughezzani1, Maxine Sun1, Shahrokh F. Shariat1, Hugues Widmer1, Markus Graefen2, Francesco Montorsi3, Pierre I. Karakiewicz1 University of Montréal, Montréal, QC, Canada; Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany; 3Vita-Salute San Raffaele, Milan, Italy 2 P128. A Population-Based Analysis of the Rate of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma in the United States Daniel Liberman1, Claudio Jeldres1, Sara Baillargeon-Gagne1, Hendrik Isbarn1, Umberto Capitanio1, Shahrokh F. Shariat1, Maxine Sun1, Giovanni Lughezzani1, Paul Perrotte1, Francesco Montorsi2, Markus Graefen3, Pierre I. Karakiewicz1 University of Montréal, Montréal, QC, Canada; Rennes University Hospital, Rennes, France; 3Vita-Salute San Raffaele, Milan, Italy; 4Martiniclinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany 1 2 4:42 p.m. 1University of Montréal, Montréal, QC, Canada; 2VitaSalute San Raffaele, Milan, Italy; 3Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany 4:30 p.m. Radoslav Krouchev1, Hendrik Isbarn1, JeanJacques Patard2, Claudio Jeldres1, Maxine Sun1, Giovanni Lughezzani1, Paul Perrotte1, Pierre I. Karakiewicz1 University of Montréal, Montréal, QC, Canada; 2Martiniclinic, Prostate Cancer Hamburg-Eppendorf, Hamburg, Germany; 3Vita-Salute San Raffaele, Milan, Italy; 4Rennes University Hospital, Rennes, France 1 University of Montréal, Montréal, QC, Canada; Rennes University Hospital, Rennes, France 1 2 P130. Can Renal Mass Biopsy Assessment of Tumor Grade Be Safely Substituted with a Predictive Model? Daniel Liberman1, Claudio Jeldres1, Maxine Sun1, Alexandre de la Taille2, Jacques Tostain2, Antoine Valeri2, Luca Cindolo3, Vincenzo Ficarra4, Walter Artibani5, Richard Zigeuner2, Arnaud Mejean2, Jean Luc Descotes2, Eric Lechevallier2, Peter F. Mulders2, Francesco Montorsi6, Paul Perrotte1, Jean-Jacques Patard2, Pierre I. Karakiewicz1 P133. Nephron-Sparing Surgery Is Equally Effective to Radical Nephrectomy for T1bN0M0 Renal Cell Carcinoma: A Population-Based Assessment. Nawar Hanna1, Maxime Crepel1, Claudio Jeldres1, Paul Perrotte1, Umberto Capitanio1, Hendrik Isbarn1, Shahrokh F. Shariat1, Giovanni Lughezzani1, Maxine Sun1, Philippe Arjane1, Hugues Widmer1, Markus Graefen2, Francesco Montorsi3, Jean-Jacques Patard4, Pierre I. Karakiewicz1 P129. Tumor Necrosis Is Not an Informative Marker of Cancer-Specific Mortality in Patients with all Stages of Renal Cell Carcinoma 4:33 p.m. P132. A Comparative Population-Based Analysis of the Rate of Partial vs. Radical Nephrectomy for Clinical Localized Renal Cell Carcinoma Salima Ismail1, Sara Baillargeon-Gagne1, Claudio Jeldres1, Giovanni Lughezzani1, Hendrik Isbarn1, Umberto Capitanio1, Shahrokh F. Shariat1, Maxime Crepel1, Maxine Sun1, Hugues Widmer1, Philippe Arjane1, Jean-Jacques Patard2, Paul Perrotte1, Francesco Montorsi3, Markus Graefen4, Pierre I. Karakiewicz1 1 4:27 p.m. P131. For T1an0m0 Renal Cell Carcinoma, Lymph Node Invasion in Patients with Metastatic Renal Cell Carcinoma: A Population-Based Perspective 4:45 p.m. P134. Simplified Fuhrman Grade Is Equally Informative to the Conventional Fuhrman Grade: A Population-Based Analysis Maxine Sun1, Giovanni Lughezzani1, Claudio Jeldres1, Hendrik Isbarn1, Philippe Arjane1, Hugues Widmer1, Daniel Pharand1, Shahrokh F. Shariat1, Francesco Montorsi2, Paul Perrotte1, Pierre I. Karakiewicz1 University of Montréal, Montréal, QC, Canada; 2VitaSalute San Raffaele, Milan, Italy 1 29 4:48 p.m. Discussion 5 p.m. Adjourn 5:30 – 6:30 p.m. Residents’ Reception 7 – 10 p.m. Fun Night at Cirque Éloize N U RS I NG PROG RAM FRIDAY, OCTOBER 9, 2009 7:30 a.m. – 4 p.m. Fairmont Queen Elizabeth SATURDAY, OCTOBER 10, 2009 6:30 – 7:30 a.m. Industry-Sponsored Breakfast Symposium Saint Laurent/Gatineau 7:30 – 8 a.m. 8 – 8:15 a.m. Revisiting Testosterone Levels Achieved with Androgen Ablation: What is Optimum Suppression? Judd Moul, Duke University Medical Center, Durham, North Carolina, United States President, Northeastern Section of the AUA Frances Stewart, RN Past President, Urology Nurses of Canada 8:15 – 9 a.m. Annual Business Meeting Residents’ Breakfast How to Select a Urology Fellowship Program 8:30 – 8:45 a.m. 8:45 – 9:30 a.m. Shahrokh Shariat, Dallas, Texas, United States Best-Of-Poster Session Presented by moderators of previous day’s poster sessions Slotkin Lecture J. Curtis Nickel, MD Kingston General Hospital, Kingston, ON, Canada 9 – 9:45 a.m. University of Western Ontario, London, ON, Canada 9:45 – 10:15 a.m. Break in Exhibit Hall 10:15 – 11 a.m. Screening for Prostate Cancer with PSA: Significance of Recent Screening Studies Edward M. Messing, MD University of Rochester, Rochester, NY, United States 11 a.m. – Noon Consultant Pediatric Urologist, London, England Queensway Carllton Hospital, Ottawa, ON, Canada Moderator: Pierre Karakiewicz Welcome and Introduction Androgen Deprivation Therapy Edward M. Messing Moderator: TBD Noon – 1:30 p.m. Lunch in Exhibit Hall 1:30 – 2:30 p.m. Women's Incontinence Martine Jolivet-Trembley, MD University of Rochester, Rochester, New York, United States Panelists: Alexandre R. Zlotta and D. Andrew Loblaw 10:15 – 10:45 a.m. Break 10:45 a.m. Plenary Session VII Moderator: Anne-Marie Houle 10:45 a.m. 10:50 a.m. Welcome and Introduction Urinary Obstruction from the Cradle to the Grave Sir Phillip Ransley Consultant Pediatric Urologist, London, England 11:20 a.m. Stress Urinary Incontinence and Unstable Bladder Panelists: Jerzy Gajewski and Sender Hershorn Moderators: Luc Valiquett, Serge Carrier and Martine Jolivet-Tremblay Innovative Nursing Roles in a New Regional Cancer Surgery Program Susan Freed, RN, BScN 9:30 – 10:15 a.m. Plenary Session VI 9:30 a.m. 9:35 a.m. The Role of Nursing in Management of the Couple with ED/Infertility Gerald Brock, MD, FRCSC Sun, Light and Shadows Moderator: Anne-Marie Houle Sir Phillip G. Ransley Education Session Prostatitis: A Phoenix Rising from the Ashes Sponsored by Ferring Pharmaceuticals 7:30 – 8:30 a.m. 7:30 – 8:30 a.m. Breakfast Welcome Anne-Marie Houle, MD University of Montréal, Montréal, QC, Canada 2:30 – 3:15 p.m. Children’s Incontinence and Biofeedback Program Catherine Daniels, RN, MS, ACNP Hospital for Sick Children, Toronto, ON, Canada 3:15 – 4 p.m. TURP Syndrome Revisited Carol-Anne Lee-Desmarais, RN, BN McGill University Health, Royal Victoria Hospital, Montréal, QC, Canada Continuing Nursing Education Credits This activity has been submitted to the Society of Urologic Nurses and Associates (SUNA) for approval to award 5.75 contact hours. SUNA is accredited as an approver of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. University of Montréal, Montréal, Quebec, Canada 30 Noon 12:30 p.m. 12:30 – 4 p.m. 6:30 – 10 p.m. Adjourn Tennis Tournament Historic Tour of Old Montréal President’s Reception & Banquet Northeastern Section of the AUA — 2009 Annual Meeting Social Program N ETWORKI NG RECEPTION Complimentary Thursday, October 8, 2009 Time: 7 – 9 p.m. Location: Fairmont Queen Elizabeth Hotel Drop the gloves and shake hands with your colleagues at the Opening Day Networking Reception. Help celebrate the 100th anniversary of the Montréal Canadiens hockey team. Food, beverages and entertainment will be provided. Come, network with your colleagues and friends and enjoy! TOU RS The following tours have been reserved for guests on Friday, October 9 and Saturday, October 10, 2009. Each tour group will meet at the Mansfield entrance in the lobby of the Fairmont Queen Elizabeth Hotel prior to departure. Guests are encouraged to pre-register for tours when they pre-register for the conference, as spots will fill quickly. On-site tour registration will take place at the hotel on Thursday, October 8 between 7 a.m. and 5 p.m. and will be available on a first-come, first-served basis. Payments can be made on site at the hotel for any tours that have not been pre-registered or pre-paid. Please note that if minimum numbers are not met, tours will be cancelled. Friday, October 9, 2009 Tour Option: Tour Time: Cost: Botanical Garden, Insectarium & Biodôme 9 a.m. – 3 p.m. $57 [Includes taxi transportation; professional tour guide; entrance admission to the Botanical Gardens, Insectarium and Biodôme; guide and driver gratuities; and all applicable taxes.] Travel by reserved cab to spend a fabulous day exploring Montréal’s flora and fauna! The Montréal Botanical Garden (Le Jardin Botanique) houses a collection of 22,000 plant species and cultivars, 10 exhibition greenhouses, 30 thematic gardens, as well as teams of researchers and informative staff. The Montréal Botanical Garden ranks as one of the world’s largest and most spectacular botanical gardens. A magical exhibition of lanterns will be on display in the Chinese Garden while we are there. We will also explore the ever-popular Montréal Insectarium— located adjacent to the Botanical Garden—which has welcomed hundreds of thousands of visitors intrigued by these misunderstood creatures, so often wrongly feared and despised. The goal of the Insectarium is to awaken visitors to the wonders of the insect world, and to explain how insects play an essential part in ensuring the Earth’s ecological balance. Following the Insectarium tour, the group will be escorted across the street and through the site of the 1976 Olympic Games to what was originally designed as the cycling track. An oasis in the heart of the city, the facility has been transformed into the Montréal Biodôme, which recreates four distinct climates that are home to the native flora and fauna of the region, truly some of the most beautiful ecosystems of the world: the lush and humid Tropical Forest, the Laurentian Forest, the St. Lawrence Marine Ecosystem, and the Polar Worlds of the Arctic and Antarctic. Once the tour of the Biodôme has come to an end, you will take reserved taxi cabs back downtown where you’ll find a variety of restaurants and an excellent opportunity to explore the downtown core with an experienced guide. Following lunch on your own, you will be escorted back to the hotel. Saturday, October 10, 2009 Tour Option: Tour Time: Cost: Old Montréal Historical Tour 12:30 – 4 p.m. $63 [Includes transportation, professional tour guide, Pointe-àCallière Museum entrance fees, guide and driver gratuities, and all applicable taxes.] Montreal City Hall 31 From the place where the city was founded in 1642 at Pointe-à-Callière, to the lively destination of Place Jacques Cartier, you’ll explore the rich history of this spectacular metropolis. With simplicity and humor, your guide will lead your group through a maze of cobblestone streets and historic buildings for a unique look at Old Montréal. The coach will drop off the guests at Pointe-àCallière for a tour of the Museum, and from there a guide will escort the group through Old Montréal—from Place d’Armes and Place Royal, to the Court houses, Château Ramezay and Bonsecours Market—offering a charming look at this city’s rich history. The Lachine Canal path, with more than one million visitors each year, is the most popular path in Canada. It extends more than 11 km (7 miles) and is a national historic site. Its banks, while welcoming to cyclists, runners and strollers, are also considered the cradle of industrialization in Canada. For breathtaking scenery with a historic touch, this is the place to be. You can pre-register for this event when you preregister for the conference on the Web site, or you can register on site. Prizes will be given to the top three male and female runners. NS-AUA 5k Run/Walk for Residents Courrir/Marcher pour les résidents Montréal TEN N I S TOU RNAM ENT Saturday, October 10, 2009 Friday, October 9 2009, 6:30 a.m. Vendredi, 9 Octobre 2009, 6:30 Time: 12:30 – 3:30 p.m. Location: Nuns’ Island Indoor Tennis Club Cost: $30 [Includes tennis balls, hand towels, water, sports drinks, sodas, fruit and granola bars.] 5K RU N FOR RES I DENTS For Runners and Walkers Friday, October 9, 2009 Time: 6:30 – 8 a.m. (Race begins at 7 a.m.) Location: Lachine Canal Cost: $15 [Includes run t-shirt, water, fresh fruit and granola bars.] Note: All proceeds go toward the Section’s Foundation in support of educational and research grants for residents. Enjoy our tennis tournament at the Nuns’ Island Indoor Tennis Club. With 20 hard courts and under the directon of Conrad Pineau, Nun’s Island is the leader in Canadian tennis. Without a doubt, their school of tennis is the reason for the club’s success. You can preregister for this event when you register for the conference or you can register on site when you arrive. S POU S E LOU NG E Location: Suite 1742 – John Lennon Suite 32 Come run (or walk) for residents! Or, if you prefer, be a sleepwalker —stay in bed and contribute $15 to the Section’s Foundation in support of educational and research grants for residents. The air is clean and crisp and the sun rises as you arrive to register for the race. Colorful rays glisten along the regal Lachine Canal as you take in the scenic area. Trees lining the canal from the Old Port to Lac SaintLouis sprinkle their leaves along the path in vivid fall tones. With your running shoes laced and a water bottle in hand, you’re ready to go! The celebrated singer-songwriter John Lennon and his wife Yoko Ono choose the suite 1742 at the Fairmont The Queen Elizabeth hotel for their “Bed-in.” This historical event for peace began on May 26, 1969. The highlight of this significant event was John Lennon’s composition of the song ‘’Give Peace a Chance’’. Hours of Availability: Thursday, October 8: 7 – 9 a.m. Friday, October 9: 7 – 9 a.m. Saturday, October 10: 7 – 9 a.m. Northeastern Section of the AUA — 2009 Annual Meeting & Reception at 6:30 p.m., Banquet, Program and Awards at 7 p.m. Attire: Semi-formal attire Cost: If you have registered for the NS-AUA’s 2009 Annual Meeting, you will receive one complimentary ticket (Residents receive two tickets). Additional tickets are $75 and can be purchased at the Registration Desk. Join us for a reception and dinner with keynote speaker, Richard Béliveau, PhD. Dr. Béliveau obtained his PhD from Université Laval and went on to complete his post-doctoral training at Cornell University in New York. He holds the Chair for Cancer Prevention and Treatment at Université du Québec à Montréal and has been a professor in its Biochemistry Department since 1984. He is the author of several books on foods that fight cancer. He is also an associate professor in the Department of Surgery at Université de Montréal. Dr. Béliveau has been Director of the Molecular Medicine Laboratory at Sainte-Justine Hospital since 1996. He is also a member of the Department of Hemato-Oncology at Sainte-Justine, of the Neurosurgery-Oncology division at the Centre Hospitalier de L’Université de Montréal (CHUM) and of the Montréal Centre for Experimental Therapeutics in Cancer (MCETC) at the SMBD-Jewish General Hospital. The fight against cancer is at the heart of Dr. Béliveau’s scientific and humanitarian efforrts. His team, comprised of 35 people, works on three main projects: brain tumors and the blood-brain barrier, tumor vascularization (angiogenesis) and the prevention of cancer through nutrition (nutraceuticals). Dr. Béliveau and the hotel chef have designed the menu for this event to coincide with his cancer-fighting research in the area of nutrition. Quick Guide to Montréal Meeting and Accommodations Location: Fairmont The Queen Elizabeth Hotel 900 René–Lévesque Boulevard West Montréal, Québec, Canada H3B 4A5 Phone: 1-514-861-3511 or 1-800-441-1414 Fax: 1-514-954-2256 Hotel Web site: www.fairmont.com/queenelizabeth TOU RI ST I N FORMATION: Visit www.tourisme-montreal.org to learn more about the host city for this year’s Annual Meeting. Highlights: I Old Montréal: The city’s enchanting historic quarter, with cafés, cobblestones and gourmet restaurants, a mix of Old World charm and modern flair. I Sainte-Catherine Street: Canada’s shopping mecca with 1,200 stores over a nine-mile (15- km) stretch of downtown Montréal. I The Underground Pedestrian Network: Boasting more than 20 miles (33 km) of weather-protected passageways, this unique pedestrian walk connects you to the subway, shops, restaurants, movie theatres and more. I Get your culture fix at the Museum of Fine Arts, Musée D’Art Contemporain, Canadian Centre for Architecture, Redpath Museum and McCord Museum of Canadian History. I Outdoor activities include more than 1,000 parks, water sports and cruises along the majestic St. Lawrence River, plus bike paths galore. I As North America’s gastronomic capital, Montréal features over 6,500 restaurants representing 80 different cultures. WEATH ER: The weather in Montréal varies depending on the season, so you are encouraged to check the forecast before packing. The average high temperature in October is 55° Fahrenheit (13°C).The average low temperature is 39° Fahrenheit (4°C). AI RPORT: Pierre Elliott Trudeau International Airport Web site: www.admtl.com The main Canadian airport east of the Great Lakes, Montréal-Trudeau’s world-class air terminal is designed to provide you with the most efficient, comfortable and safe airport experience possible. Every year, about 40 air carriers transport more than 11 million passengers via Montréal-Trudeau. There are direct flights to and from approximately 120 regular and seasonal destinations in Canada, the United States and internationally. TRAN S PORTATION: L’Aérobus: Service provides an efficient connection by motor bus between Montréal-Trudeau airport and downtown Montréal. Cost: $15 Canadian Dollars (CAD) one-way for an adult, $25 CAD roundtrip Hours: Departures are 24 hours a day. Detailed schedule is available at www.autobus.qc.ca/anglais/horaire_an.html. Travel time is 30-45 minutes, depending on traffic. Reservations: Not required. Tickets can be purchased at the Montréal Central Bus Station and at MontréalTrudeau (arrivals level). Taxis: Taxis and limousines are available at the airport at the arrivals level near the central exit located in front of the cloakroom. The fixed fare for Downtown is $38 CAD for a taxi or $49.50 CAD for a limousine. Visa, MasterCard and American Express credit cards are accepted. Some drivers accept U.S. currency but provincial regulations require customers to pay in Canadian currency. RENTAL CARS: Avis is offering special discounted rates to all meeting attendees. Reservations can be made by calling: 1-800-331-1600 Hearing Impaired/TDD 1-800-331-2323 Spanish Translation 1-800-874-3556 Use the AUA Discount code: J907607 HOTEL I N FORMATION: Fairmont The Queen Elizabeth Hotel Location: Located in the heart of downtown Montréal, walking distance to all major attractions, the Fairmont is a landmark, superior class hotel connected to the world famous underground city and subway. It is situated directly over Central Station. Room Rates: $179 CAD Single/Double per night, $249 CAD Triple Reservation Cut-off Date: August 28, 2009 Important Note: Rooms are available on a first-come first-served basis. The NS-AUA is holding a block of rooms at the hotel listed above. It is advised that you book reservations at your earliest possible convenience. The room block may sell out prior to the cut-off date for reservations. Should this occur the NS-AUA is unable to guarantee additional reservations at this hotel. 35 Check-in: 4 p.m. Check-out: Noon Credit Cards Accepted: Amex, Visa, Diners, Discover and Master Card Parking: Valet parking is available for $26 CAD/night with unlimited in/out access. Fitness Center: The Health Club is complimentary to all guests and is accessible from 6 a.m. to 10 p.m. daily. It will invigorate you with its indoor pool, steam room, whirlpool, state-of-the-art “Keiser” equipment and a variety of cardiovascular machines. Room Service: Available 24 hours, 7 days a week. Hotel Restaurants: Guestroom Common Amenities (all rooms offer the following amenities): I coffee maker including complimentary coffee/tea I mini-bar I iron and ironing board I hairdryer I color television with remote control and cable with in-room pay-per-view movies I alarm clock-radio I telephone with voicemail I individual climate control Guestroom Amenities on Request (the following amenities may be available – please indicate the request in your reservation or ask one of the reservation agents): I connecting rooms I cribs I mini-refrigerator (extra $20 CAD) I sofa bed I special needs amenities: alarm clock-radio (vibrating); amplifier for partially hearing-impaired guests; bathroom with grab-bar and adapted height for the toilet, lower sink; door knock sensor; flashing light for call/smoke detector alert; telecaption for TV and TTY Business Center: XEROX, a full service business center, is located on the lower lobby level (Level S1) and can assist you with all of your business needs. Services include work stations with high-speed Internet access, color and black-and-white printing/copying, fax services and scanning. It is open Monday through Friday, 8 a.m. to 5:30 p.m. Internet Service: Wired Internet access is available in every guest room for $13.95 CAD plus taxes for 24 hours. However, if you are a member of the Fairmont’s President Club prior to your arrival, you can benefit from free Internet access in your guest room. See below for additional details. 36 I Le Montréalais: Bistro style, casual restaurant serving breakfast, lunch, dinner and Sunday brunch. Open 7 days a week, 6:30 a.m. to 11 p.m. I Beaver Club: French cuisine, jacket required, rated one of Canada’s top 10 restaurants – AAA 4 Diamond award-winner Lunch – Monday through Friday, Noon to 3 p.m. Dinner – Tuesday through Saturday, 6 to 11 p.m. I Les Voyageurs: Bar/lounge serving lunch, dinner and light snacks Monday through Friday, Noon – 1 a.m. Saturday and Sunday, 4 p.m. – 1 a.m. I Tea Lounge: Open Monday through Sunday, 2:30 – 6 p.m. Gift Shops: Gift shops are located on the lobby level of the hotel. Also, the hotel is connected to Place Ville Marie, an underground shopping area with more than 60 stores. Babysitting: Bonded babysitters are available, with a four-hour minimum notice required. The price for one or two children is $20 CAD/hour with a three-hour minimum charge. Additional costs apply for three or more children. Reservations can be made through the Concierge Desk. Pets: Pets less than 20 pounds are permitted in the hotel. A charge of $25 CAD/day will apply. The animal must be kept in a kennel at all times and must not be left unattended in the room. Seeing-eye dogs are always welcome and are exempt of charges and restrictions. Fairmont President’s Club: Fairmont Hotels & Resorts’ exclusive guest recognition program, Fairmont President’s Club, offers special benefits and privileges designed to reflect your individual travel preferences. Membership is complimentary and your experience begins the moment you arrive at the Fairmont with express check-in. You will also receive complimentary high-speed Internet access in your guest room, free local calls, complimentary daily newspaper and more. Please visit www.fairmont.com/fpc to enroll, and remember that you must enroll prior to your arrival to benefit from the privileges. Northeastern Section of the AUA — 2009 Annual Meeting Exhibitor Listing (Alphabetical) ALLERGAN, INC. 21 2525 Dupont Drive BOSTON SCIENTIFIC Irvine, CA 92612 USA Marlboro, MA 01752 USA Phone: 714-246-4500 Phone: 508-650-8000 Web site: www.Allergan.com Web site: www.bostonscientific.com Allergan, Inc. is a multi-specialty healthcare company. We are pleased to offer a number of leading products, including: SANCTURA XR™ (trospium chloride extended release capsules), BOTOX® (Botulinum Toxin Type A), RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%, LUMIGAN® (bimatoprost ophthalmic solution) 0.03%, and BOTOX® Cosmetic (Botulinum Toxin Type A). AMERICAN MEDICAL SYSTEMS 5 100 Boston Scientific Way 66 Boston Scientific is a leading developer of less invasive technologies. Our products include devices for the treatment of kidney stones, BPH, female urinary incontinence and pelvic floor reconstruction. Please visit us to learn about our newest technologies. CALMOSEPTINE, INC. 69 75 York Street, Suite 1508 Kitchener, Ontario N2G 1T5 CANADA 10700 Bren Road West Phone: 519-741-9295 Minnetonka, MN 55343 USA Web site: www.calmoseptineointment.com Phone: 952-930-6000 Web site: www.AmericanMedicalSystems.com American Medical Systems is a world leader in medical devices and procedures that treat four major diseases: incontinence, prolapse, erectile dysfunction and benign prostate hyperplasia (BPH). Any one of these conditions can profoundly diminish a patient’s quality of life and significantly impact relationships. Our products provide a cure or reduce the incapacitating effects of these diseases, often through minimally invasive surgery. ASTELLAS PHARMA CANADA, INC. 71 Calmoseptine Inc. promotes Calmoseptine® Ointment for the prevention and treatment of skin irritations from moisture such as urinary and fecal incontinence. It is also effective for irritations from perspiration, wound drainage, fecal and vaginal fistulas and feeding tube site leakage. Calmoseptine® Ointment temporarily relieves discomfort and itching. Free samples at our booth! COLOPLAST CORP. 73 1601 West River Road North Minneapolis, MN 55411 USA Phone: 612-337-7800 675 Cochrane Drive, Suite 500, West Tower Web site: www.straighttalk.com Markham, Ontario L3R 0B8 CANADA Phone: 905-470-7990 Web site: www.astellas.com/ca/en/ Astellas Pharma US, and Astellas Pharma Canada are affiliates of Tokyo-based Astellas Pharma Inc., a pharmaceutical company dedicated to “Changing tomorrow” by improving the health of people around the world through innovative and reliable pharmaceutical products. For more information please visit our Web sites at www.astellas.com/us, and www.astellas.com/ca. Coloplast is a leading global manufacturer and marketer of innovative medical devices for the management and treatment of urological disorders to include incontinence, retention and ED. Stop by booth 73 to learn about our new Virtue male sling, the alternative approach to treating stress urinary incontinence. COOK MEDICAL INCORPORATED 14 P.O. Box 489 Bloomington, IN 47401 USA AUXILIUM PHARMACEUTICALS, INC. 78 Phone: 800-468-1379 40 Valley Stream Parkway Phone: 812-339-2235 Malvern, PA 19355 USA Phone: 812-339-3704 Phone: 484-321-2136 Web site: www.cookmedical.com Web site: www.auxilium.com Auxilium engages in the global development, marketing, and sales of ethical pharmaceutical products that maintain functionality in an aging male population. Auxilium’s lead product, Testim® 1% (testosterone gel) CIII, is indicated for the treatment of hypogonadism. Auxilium's continued focus is in developing/acquiring novel molecules with viability in the urological field. Cook Medical was one of the first companies to help popularize interventional medicine, pioneering many of the devices now commonly used worldwide to perform minimally invasive medical procedures. Today, the company integrates minimally invasive medical device design, biopharma, gene and cell therapy, and biotech to enhance patient safety and improve clinical outcomes in the fields of aortic intervention; interventional cardiology; critical care medicine; gastroenterology; radiology, peripheral vascular, bone access and oncology; surgery and soft tissue repair; urology; and assisted reproductive technology, gynecology and high-risk obstetrics. Founded in 1963 and operated as a family-held private corporation, Cook is a past winner of the prestigious Medical Device Manufacturer of the Year Award from Medical Device & Diagnostic Industry magazine. 37 DENDREON CORPORATION 18 FERRING PHARMACEUTICALS 3005 First Avenue 4 Gatehall Drive, 3rd Floor Seattle, WA 98121 USA Parsippany, NJ 07054 USA Phone: 206-256-4545 Phone: 973-796-1600 Web site: www.dendreon.com Phone: 1-888-FERRING (337-7464) Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. ELI LILLY CANADA, INC. 25 60 3650 Danforth Avenue Scarborough, Ontario M1N 2E8 CANADA Web site: www.ferringusa.com Web site: www.firmagon.com Ferring Pharmaceuticals announces new FIRMAGON® (degarelix for injection), the trade name for degarelix. Ferring previously introduced Prosed® DS. Ferring Pharmaceuticals specializes in six therapeutic areas: urology, infertility, obstetrics, gastroenterology, endocrinology, and osteoarthritis. HEALTHTRONICS, INC. Phone: 416-693-3790 36 9825 Spectrum Drive, Building 3 Web site: www.lilly.ca Austin, TX 78717 USA Eli Lilly is a leading, innovation-driven pharmaceutical corporation committed to providing answers that matter through medicines and information, for some of the world's most urgent medical needs. Lilly, une société pharmaceutique de pointe axée sur l’innovation est résolue à apporter des réponses qui comptent, sous forme de médicaments et d'informations, pour certains des impératifs médicaux les plus urgents dans le monde. ELSEVIER CANADA 8 905 King Street West, 4th Floor Phone: 512-328-2892 Web site: www.healthtronics.com HealthTronics® is the leading provider of urology products and services offering the latest technology in prostate therapies for BPH and cancer, lithotripsy and uropathology services. Through ClariPath Laboratories®, our anatomic pathology laboratory, we offer multiple business solution models and the most advanced technology available ensuring accurate results and rapid turnaround times. INTUITIVE SURGICAL, INC. Toronto, Ontario M6K 3G9 CANADA 1266 Kifer Road, Building 101 Phone: 416-644-7090 Sunnyvale, CA 94086 USA Web site: www.elsevier.com Phone: 408-523-2100 Elsevier Canada is a team of leading publishers including Saunders, Mosby, Churchill Livingstone, Butterworth-Heinemann, Hanley & Belfus, MDConsult and FIRSTConsult dedicated to meeting the information needs of health science professionals. We publish high-quality textbooks, references, periodicals, and electronic products for medicine, nursing, dentistry, veterinary medicine, and health professions. ENDO PHARMACEUTICALS 4 100 Endo Boulevard 3 Web site: www.intuitivesurgical.com Intuitive Surgical, Inc. is shaping the future of urologic minimally invasive surgery. The da Vinci® Prostatectomy represents the number one treatment for prostate cancer in the United States today, leveraging the da Vinci® Surgical System’s state-of-the-art technology. Visit www.daVinciProstatectomy.com and www.daVinciSurgery.com today. Chadd's Ford, PA 19317 USA KARL STORZ ENDOSCOPYAMERICA, INC. Phone: 610-558-9800 2151 East Grand Avenue Web site: www.endo.com El Segundo, CA 90245 Endo Pharmaceuticals is a specialty pharmaceutical company with a broad portfolio of branded and generic prescription products focused on providing relief from pain. Endo is dedicated to improving the lives of patients through identifying, developing, and marketing innovative and differentiated products in pain management and related therapeutic areas, including urology and endocrinology. Web site: www.karlstorz.com KARL STORZ Endoscopy-America, Inc., a leader in endoscopic equipment and instruments, markets products that emphasize visionary design and precision craftsmanship. Our urology line includes the revolutionary flexible video cystoscopes, combining the versatility of flexible endoscopes with advanced distal chip technology. We also offer the industry’s only STERRAD® NX™/100NX™-compatible flexible fiberscopes. 38 Northeastern Section of the AUA — 2009 Annual Meeting 19 KARL STORZ LITHOTRIPSY-AMERICA, INC 19 PD LABS 1000 Cobb Place Boulevard 19230 Stone Oak Parkway #200 22 Building 400 Suite 450 San Antonio, TX 78258 USA Kennesaw, GA 30144 Phone: 210-494-1678 Web site: www.karlstorz.com Web site: www.pdlabs.com The Storz MODULITH® SLX-F2 is a one-of-a-kind lithotripter as well as a diagnostic and therapeutic workstation. Equipped with patented, electromagnetic shock wave technology, offering selectable focus as well as in-line ultrasound and X-ray localization capabilities, the F2 provides unparallel reliability and precision in treatment. With more than 700 various systems operating worldwide, Karl Storz Lithotripsy - America, Inc. provides nationwide sales and customer support, service technicians. Prescription Dispensing Laboratories, a compounding and research pharmacy, has developed and patented the use of a calcium channel blocker (i.e. Transdermal Verapamil 15%) for the non-invasive, transdermal treatment of Peyronie’s disease and other fibrotic connective tissue disorders. MCUBE TECHNOLOGY CO., LTD New York, NY 10017 USA PFIZER INC 67 235 East 42nd Street 12 Room # 803 Shinnae - Technotown, 485, Phone: 212-733-2323 Sangboong - Dong, Chungnang-Gu Web site: www.pfizer.com Seoul, 131-220 KOREA Please visit the Pfizer Inc, Worldwide Pharmaceuticals exhibit featuring: TOVIAZ™ (fesoterodine fumarate) extended release tablets 4mg and 8mg Phone: 82-2-3421-7780 Web site: www.mcubetech.co.kr Mcube manufactures and exports Ultrasonic Bladder Scanner[BioCon500] under CE and FDA. BioCon500™ measures volume of remaining urine inside bladder. It’s useful for treatment, surgery, and rehabilitation in lower urinary tract disorders, due to its non-invasive method. Decrease in frequency of catheterization reduces rate of urinary tract infection and patients’ pain. Founded in 1849, Pfizer is the world's largest research-based pharmaceutical company taking new approaches to better health. We discover, develop, manufacture and deliver quality, safe and effective prescription medicines to treat and help prevent disease for both people and animals. PROUS SCIENCE OCEANA THERAPEUTICS, INC. 61A 2035 Lincoln Highway, Suite 2150 150 Crows Foot Lane Centreville, MD 21617 USA Edison, NJ 08817 USA Phone: 410-490-0307 Phone: 732-318-3815 Web site: www.prous.com Web site: www.oceanathera.com Oceana Therapeutics, Inc. markets and sells Deflux® for the treatment of vesicoureteral reflux (VUR) grades II-IV in children in the United States. Please take a moment to discover Oceana Therapeutics at www.oceanathera.com or visit www.deflux.com. Timely Topics in Medicine - Urology (www.ttmedurology.com) is a FREE professional educational Web site for urologists and those interested in the field of urology. Highlights on the site include Webcast presentations from the AUA Annual Meeting and AUA sectional meetings as well as the World Robotic Urology Symposium, SUFU, FUUS, ISU and EAU. QDX PATHOLOGY SERVICES OLYMPUS 81 72 136 Turnpike Road Cranford, NJ 07016 Southborough, MA 01772 USA Phone: 1-866-909-PATH Phone: 508-804-2600 Web Site: www.qdxpath.com Web site: www.gyrusacmi.com Olympus and Gyrus ACMI, two of the world’s leading suppliers of minimally invasive surgical technologies have joined forces to create a more versatile organization. The best-in-class tissue management systems of Gyrus ACMI perfectly complement the innovative array of world-class medical systems and leading-edge opto-digital technology offered by Olympus. 68 46 Jackson Drive QDx Pathology Services is an independent, CLIA certified, state-ofthe-art pathology company, specializing in anatomic pathology, as well as cytopathology, and a full range of ancillary services. Our staff of experienced, board-certified pathologists and cytotechnologists are dedicated to providing clinicians and patients with diagnostic excellence. 39 Q-MED, INC. 6 504 -703 Evans Avenue, Suite 504 THE CANADIAN JOURNAL OF UROLOGY 1 2330 Ward Street, Suite 604 Toronto, Ontario M9C 5E9 CANADA St. Laurent, Quebec H4M 2V6 CANADA Phone: 416-513-1323 Phone: 514-744-1184 Web site: www.q-med.com Web site: www.canjurol.com Deflux™, for the paediatric treatment of vesicoureteral reflux (VUR), is a biocompatible substance manufactured according to Q-Med’s patented technology of *NASHA, including dextranomer. It is a safe and effective endoscopic procedure and has been used worldwide to successfully treat over 50,000 children. The Canadian Journal of Urology (CJU), is a peer reviewed indexed urology journal published six times per year. Indexed in Index Medicus/MEDLINE and Current Contents/Clinical Medicine. Since its inception in 1994 we have steadily gained recognition in Canada, United States and the international urological community. We welcome your submissions. *NASHA = Non-Animal Stabilized Hyaluronic Acid SANOFI-AVENTIS CANADA, INC. 70 2150 St. Elzear Boulevard W VISION-SCIENCES, INC 34 40 Ramland Road South Orangeburg, NY 10962 USA Laval, Quebec H7L 4A8 CANADA Phone: 845-365-0600 Phone: 800-265-7927 Web site: www.visionsciences.com Web site: www.sanofi-aventis.ca Sanofi-aventis is represented in Canada by the pharmaceutical company sanofi-aventis Canada Inc., based in Laval, Quebec, and by the vaccines company Sanofi Pasteur Limited, based in Toronto, Ontario. Together they employ more than 2,000 people and are leaders in Canada’s biopharmaceutical sector, a critical research-based industry that generates jobs, business and opportunity throughout the country. SANOFI-AVENTIS U.S. 76 55 Corporate Drive Vision-Sciences redefines cystoscopy with its new flexible video cystoscope and sterile, disposable EndoSheath® System. Physicians can now have revolutionary full screen imaging and advanced endoscopic functionality combined with rapid EndoSheath® turnaround time, which improves patient throughput. Additionally, EndoSheath® cystoscopy reduces staff exposure to toxic chemicals, and increases scope life while minimizing capital, service and maintenance costs. VIVUS, INC. 17 1172 Castro Street Mountain View, CA 94040 USA Bridgewater, NJ 08807 USA Phone: 650-934-5200 Phone: 908-981-6656 Web site: www.muserx.net Web site: www.sanofi-aventis.com Sanofi-aventis U.S. is an affiliate of sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). For more information, visit www.sanofi-aventis.us or www.sanofi-aventis.com. STAMEN MEDICAL SYSTEMS 61 4811 Technology Drive VIVUS, Inc. is a pharmaceutical company dedicated to the development and commercialization of next-generation therapeutic products addressing obesity and sexual health. For more information on clinical trials and products, including MUSE® (alprostadil) urethral suppository and ACTIS® adjustable constriction loop, visit the VIVUS web site at www.vivus.com. WATSON PHARMACEUTICALS 23 360 Mt. Kemble Avenue Morristown, NJ 07960 USA Martinez, GA 30907 USA Phone: 973-355-8300 Phone: 706-863-7100 Web site: www.watson.com Web site: www.stamenmedicalsystems.com Stamen Medical Systems offers the new Erec-Tech™ and Stamen Therapy-ED. The Erec-Tech™ is the premier vacuum therapy system. Erec-Tech’s™ new features will allow patients ease of use as well as the best treatment results possible with a vacuum therapy system. We also have the most up to date patient education materials available. Stamen Therapy-ED is a great form of penile rehabilitation for patients following radical prostatectomy. Watson is dedicated to improving the lives of affected patients and advancing the practice of urology in the United States and around the globe. With developmental therapeutic innovations for BPH and cystitis, and with current therapeutic innovations for prostate cancer, overactive bladder (OAB), testosterone replacement, and testicular hypogonadism function, Watson Urology is committed to meeting the challenges in urology, today and in the future. 40 Northeastern Section of the AUA — 2009 Annual Meeting Exhibitor by Booth Number The Canadian Journal of Urology Intuitive Surgical, Inc. Endo Pharmaceuticals Boston Scientific Q-Med Inc. Elsevier Canada McCube Technology Co., Ltd. Cook Medical Incorporated VIVUS, Inc. Dendreon Corporation Karl Storz Endoscopy America, Inc & Karl Storz Lithotripsy Allergan, Inc. PD Labs Watson Pharmaceuticals Ferring Pharmaceuticals Vision Sciences, Inc. Healthtronics, Inc. Vision-Sciences, Inc Eli Lilly Canada Inc. Stamen Medical Systems Oceana Therapeutics, Inc. American Medical Systems 1 3 4 5 6 8 12 14 17 18 19 21 22 23 25 34 36 58 60 61 61A 66 Pfizer Inc QDx Pathology Services Calmoseptine, Inc. sanofi-aventis Canada, Inc. Astellas Pharma Canada, Inc. Olympus Coloplast Corp. sanofi-aventis U.S. Auxilium Pharmaceuticals, Inc. Prous Science 67 68 69 70 71 72 73 76 78 81 Get acquainted with fellow Section members and industry partners during the Exhibit Hall Reception Enjoy cocktails and hors d'oeuvres Take a shot at winning a $150 Visa gift card with our hockey game Thursday, October 8 5:30 –6:30 p.m. Exhibit Floor Plan 41 Planning Committee/Faculty/Author Disclosures Abara, Emmanuel O. Abdo, Al'a Anidjar, Maurice Azhar, Raed Bauer, Ross Berlach, David M. Bolduc, Stéphane Boucher, Andréanne 42 None None None None None None None Questionnaires and catheters were provided by Coloplast Canada Corporation, Commercial Entity, Other Budäus, Lars None Brock, Gerald B. Pfizer, Eli Lilly, Coloplast, Bayer and Johnson and Johnson: Consultant or Advisor Cardin, Allison L. None Carrier, Serge Pfizer Canada: Board Member, Officer, Trustee; Bayer Canada: Board Member, Officer, Trustee; Eli Lilly Canada: Board Member, Officer, Trustee; Solvay Canada: Board Member, Officer, Trustee Chan, Peter None Chen, Mang L. None Chu, Lei None Chughtai, Bilal None Cloutier, Jonathan None Corcoran, Anthony T. None Deschênes Rompré, Marie-Pier None Deslauriers, Valerie None Eassa, Waleed None El Sherbiny, Mohamed T. None Feuerstein, Michael A. None Fisher, Hugh GTx Inc.: Contracted Research, Commercial Entity, Other Fitzpatrick, John M. None Gagnon, Louis-Olivier None Gayed, Bishoy A. None Gingrich, Jeff GTx Inc,: Clinical Research Investigator, Commercial Entity, Other Gordetsky, Jennifer None Grober, Ethan D. None Guru, Khurshid A. None Haidar, Nadim H. None Hanna, Nawar None Hayn, Matthew None Hellenthal, Nicholas None Imbeault, Annie None Ismail, Salima None Izard, Jason None Jacobs, Bruce L. None Jeldres, Claudio None Jolivet-Tremblay, Martine None Karakiewicz, Pierre Abbot Canada: Scientific Study or Trial Kim, Brian None Klein, Eric A. Abbott Diagnostics: Research Support; Genomic Health: Research Support Klotz, Laurence None Kotb, Ahmed F. None Kovac, Jason None Krouchev, Radoslav None Kumar, Keshava N. Watson Laboratories, Inc.: Commercial Entity, Langillle, Gavin M. Laroche, Bruno Larson, Jeff Lebel, Michel Hugues Letendre, Julien Liberman, Daniel Lorenzo, Armando J. Lughezzani, Giovanni Lux, Matthew M. Luz, Murilo A. MacLellan, Dawn Mansure, Jose J. Mansure, Jose Maranchie, Jodi K. Marshall, Jonah S. McCullough, Andrew R. Mechlin, Clay W. Mendez Probst, Carlos E. Messing, Edward Moldwin, Robert Montorsi, Francesco Nadeau, Geneviève Nam, Robert K. Nassim, Roland Nickel, J. Curtis O'Flaherty, Cristian Osman, Yasser Ouellet, Gabrielle Rocha, Joice Rothschild, Jennifer G. Rutkowski, John M. Sabaa, Magdy A. Segal, Robert L. Siements, D. Robert Shariat, Shahrokh F. Singer, Eric A. Sivalingam, Sri Smaldone, Marc C. Su, Ruthie Sun, Maxine Szymanski, Konrad M. Tomaszewski, Jeffrey Underwood, Willie Vega, Roger E. Walker, Adam Wang, Ching Yafi, Faysal A. Yuh, Bertram Zlotta, Alexandre R. Employee None None None None None None None None None None None Cancer Research Society: Commercial Entity, Grant support CIHR: Commercial Entity, Grant support None None Vivus: Commercial Entity, Grant support None None None Ortho McNeil Pharmacuiticals: Consultant or Advisor; Pfizer: Consultant or Advisor, Investigator; Plethora: Investigator Pfizer, Bayer, Eli Lilly, Pierre Fabre, American Medical Systems, Glaxo Smith Klein: Consultant or Advisor CUA Abbott: Oncology Prostate Cancer Research, Commercial Entity, Grant support None None Watson Pharmaceuticals: Commercial Entity, Consultant, Investigator; Stellar: Investigator, Commercial Entity, Other None None None None None None None None Sanofi-Aventis: Investigator; Nometics: Consultant or Advisor; Merk: Investigator None None None None None None None None None None None None None None None Northeastern Section of the AUA — 2009 Annual Meeting CME Credit Form Please fill out and return to the registration counter in registration area at the conclusion of the conference. Or return to the Northeastern Section Administrative Offices at 1000 Corporate Blvd. Linthicum, MD 21090 or fax to 410-689-3837. Only mark those courses you attend. Your CME certificates will be mailed to the address provided below. AUA ID# ____________________ LAST NAME CREDENTIALS FIRST NAME ADDRESS CITY STATE/PROVINCE COUNTRY ZIP/POSTAL CODE Accreditation The American Urological Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American Urological Association takes responsibility for the content, quality and scientific integrity of this CME activity. CME Credits The American Urological Association designates this educational activity for a maximum of 18.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity Thursday 7:45 – 8:40 a.m. 8:40 – 9:45 a.m. 10:15 a.m.– Noon 10:15 a.m.– Noon 1:30 – 2 p.m. 2 – 2.45 p.m. 3:15 – 5 p.m. 3:15 – 5 p.m. ____ (1.00 credits) ____ (1.00 credits) ____ (1.75 credits) ____ (1.75 credits) ____ (0.50 credits) ____ (0.75 credits) ____ (1.75 credits) ____ (1.75 credits) Plenary I: Erectile Dysfunction (ED) After Radical Prostatectomy Plenary I: Locally Advanced and Metastatic RRC Moderated Poster Session I: Prostate Cancer Moderated Poster Session II: Basic Research Plenary II: Testosterone Supplementation & Its Risks Plenary II: Prostatitis: A Phoenix Rising Moderated Poster Session III: Robotics, Endoscopy & Laparoscopy Moderated Poster Session IV: Bladder Cancer Thursday Total ____ (6.75 possible) Friday 7:30 – 7:45 a.m. 7:45 – 8:45 a.m. 8:45 – 9:45 a.m. 9:15 – 9:45 a.m. 10:15 a.m.– Noon 10:15 a.m.– Noon 1:15 – 2:15 p.m. 2:15 – 3:15 p.m. 3:30 – 5 p.m. 3:30 – 5 p.m. Best of Poster Session Plenary III: Section Stars Plenary IV: PSA Screening State-of-the-Art Lecture 6: New Surgical Concepts for Male Infertility Moderated Poster Session V: Pediatric Urology Moderated Poster Session VI: Oncology Plenary V: Prostate Cancer Chemoprevention Plenary VI: AUA Course of Choice: Interstitial Cystitis/Painful Bladder Syndrome and Related Conditions: Practical Management Strategies Moderated Poster Session VII: General Urology Moderated Poster Session VIII: Kidney Cancer ____ (0.25 credits) ____ (1.00 credits) ____ (1.00 credits) ____ (0.50 credits) ____ (1.75 credits) ____ (1.75 credits) ____ (1.00 credits) ____ (1.00 credits) ____ (1.50 credits) ____ (1.50 credits) Friday Total ____ (8.00 possible) Saturday 7:30 – 8:30 a.m. 8:30 – 8:45 a.m. 8:45 – 9:30 a.m. 9:30 – 10:15 a.m. 10:45 – 11:20 a.m. 11:20 a.m.– Noon Residents Breakfast Program Best of Poster Session George F. Slotkin Lecture: Sun, Light and Shadows Plenary VI: Androgen Deprivation Therapy Plenary VII: Urinary Obstruction from the Cradle to the Grave Plenary VII: Stress Urinary Incontinence and Unstable Bladder ____ (1.00 credits) ____ (0.25 credits) ____ (0.75 credits) ____ (0.75 credits) ____ (0.50 credits) ____ (0.75 credits) Saturday Total ____ (4.00 possible) _____________________________________ Signature OVERALL TOTAL HOURS ____ (Total Possible Credits 18.75) Save the Date Northeastern Section AUA 2010 Annual Meeting Rich Past, Exciting Present, and Promising Future on Three Rivers Vesicare: Demonstrated Efficacy in Reducing OAB Symptoms1 Mean change from baseline OAB SYMPTOM IMPROVEMENT AFTER 12 WEEKS2 0.0 Micturitions/24 hours Urgency episodes/24 hours Urge incontinence episodes/24 hours -0.83 -0.5 -1.0 -1.42 -1.5 P=0.001 -2.0 -2.5 -3.0 -2.45 P=0.004 (non-inferiority) -2.24 Nocturia episodes/24 hours -0.71 -0.63 P=0.730 -2.42 -2.85 P=0.035 Vesicare 5 mg/10 mg OD (n=578) Tolterodine ER 4 mg OD (n=599) Adapted from Chapple et al., 2005 Prospective, double-blind, double-dummy, two-arm, parallel-group, 12-week trial in OAB patients. Patients were randomized to receive either Vesicare 5 mg OD or tolterodine ER 4 mg OD. After 4 weeks of treatment, patients had the option to request a dose increase but were dummied throughout as product labelling only allowed an increase for those on Vesicare from 5 mg to 10 mg OD. Vesicare demonstrated a greater reduction in urgency and urge incontinence episodes from baseline than tolterodine ER2 U Urgency: -47% (-2.85) Vesicare vs -41% (-2.42) tolterodine ER U Urge incontinence: -61% (-1.42) Vesicare vs -39% (-0.83) tolterodine ER INDICATIONS: Vesicare (solifenacin succinate) is indicated for the treatment of overactive bladder in adults with symptoms of urge urinary incontinence, urinary urgency and urinary frequency. Safety and effectiveness in children have not yet been established. CONTRAINDICATIONS: Patients with urinary retention, dependent on dialysis, gastroparesis or narrow angle glaucoma. Patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. Women of childbearing potential should be considered for treatment only if using adequate contraception. ADVERSE EVENTS: Expected side effects of antimuscarinic agents are dry mouth, constipation, blurred vision (accommodation abnormalities), urinary retention, and dry eyes. The most common adverse events reported in patients treated with Vesicare were dry mouth and constipation and the incidence of these side effects was higher in the 10 mg (27.6% and 13.4%, respectively) compared to the 5 mg (10.9% and 5.4%, respectively) dose group (4.2% and 2.9% for placebo, respectively). References: 1. Vesicare Product Monograph, Astellas Pharma Canada. Inc. 2008. 2. Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results from the STAR trial. Eur Urol 2005;48:464-470. Helps Control Urgency Vesicare Help your Overactive Bladder patients with the discomfort of urgency.
© Copyright 2016